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I LITERATURE REVIEW 
 
 
1 INTRODUCTION 
 
Human multidrug resistance protein 1 (MDR1), commonly known as P-glycoprotein (P-
gp) is an efflux transporter. It was first discovered in 1976 from colchicine resistant 
Chinese hamster ovary cells (Litman et al. 2001). P-gp is coded by gene ABCB1 and 
belongs to ATP-binding cassette (ABC) transporters superfamily which, according to 
their name, functions by utilizing energy from ATP.  P-gp is found in epithelial cells of 
tissues such as intestine, liver, kidneys, brain, testis, placenta and lung and it is 
expressed in many cancer cells (Litman et al. 2001, Leslie et al. 2005). Recently it was 
discovered also in ocular tissue (Senthilkumari et al. 2008). P-gp is located in cell 
membrane where it transports its substrates away from the cell interior. Its physiological 
role is to protect vital tissues such as brain and testis by preventing the entry of harmful 
compounds (Sharom et al. 2005). Another role is to promote removal of compounds 
from the body by transporting them to bile, urine and intestine (Figure 1). P-gp can 
affect drug absorption, distribution and elimination and mediate drug-drug interactions 
and therefore greatly affect the safety and efficacy of P-gp substrates (Giacomini et al. 
2010). 
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Figure 1. Location of transporter proteins and direction of transport in intestinal 
epithelia, hepatocytes, kidney proximal tubules and blood-brain barrier. P-glycoprotein 
transports substrates out from the cell in the apical membranes of intestine and blood-
brain barrier, and to the urine and bile in the kidney proximal tubule and hepatocytes, 
respectively. (Giacomini et al. 2010). 
 
P-gp is known to transport a wide selection of drugs and other compounds. During drug 
development it is vital to avoid compounds which may behave unexpectedly in the body 
and cause safety problems (EMA 2012). However, often a new drug molecule is found 
to be a transporter substrate after releasing to market. This problem could be solved if 
the structure and function of the protein is understood. If characteristics of substrate and 
its binding place are known, structures which are recognized by the protein could be 
avoided in new drug molecules. Also resistance of P-gp substrates could be overcome in 
theory by developing compounds which inhibit the function of protein (Stouch and 
Gudmundsson 2002). Understanding the mechanism of function and regulation of P-gp 
also makes it possible to control these processes (Bartolini et al. 2006).  
 
In this literature survey the structure of P-gp, mechanism of function, and regulation are 
reviewed. This is done to understand backgrounds of P-glycoprotein mediated drug-
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drug interactions. Also substrate selection and structure of P-gp substrates is viewed to 
find out if it is possible to characterize typical P-gp interacting molecule. 
 
 
2 STRUCTURAL CHARACTERISTICS OF P-GLYCOPROTEIN 
 
2.1 Structure of P-glycoprotein 
 
Human P-gp is a rather large protein composed of 1280 amino acids and weighting 170 
kDa (Hennessy and Spears, 2007). A 150 kDa P-gp intermediate is formed in 
endoplasmic reticulum and further glycosylated prior exporting to the cell surface. The 
protein seems to be formed by duplication of genes and it has two halves which both 
have 6 α-helices comprising trans-membrane domain (TMD) and nucleotide-binding 
(ATP-binding) domain (NBD) (Hennessy and Spears, 2007, Jin et al. 2012). P-gp is 
located in cell membrane with most of the molecule inside the membrane as shown in 
Figure 2. The NBD is facing interior of the cell.  
 
 
Figure 2. P-glycoprotein is located in the cell membrane with ATP (adenosine 
triphosphate) binding domains facing the interior of the cell. It comprises two halves 
which both have six trans-membrane (TM) α-helices (Fu and Arias 2012) 
 
So far the crystal structure of human P-gp has not been obtained but X-ray crystal 
structure of mouse P-gp (Figure 3) and Caenorhabditis elegans (C.elegans) PGP-1 have 
been determined (Aller et al. 2009, Jin et al. 2012). With the help of crystal structure the 
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dimensions of the protein and position of TM helices can be clarified. P-gp crystal 
structure confirms commonly accepted idea that the two halves of the protein are 
formed from six trans-membrane helices (Aller et al. 2009, Jin et al. 2012). With the 
mouse P-gp the one half is formed from TM1, 2, 3, 6, 10 and 11 and the other from 
TM4, 5, 7, 8, 9 and 12 leaving roughly 6000 Å
2
 a cavity between the two halves of 
protein (Aller et al. 2009). The height of total protein is about 70 Å, length 136 Å and 
distance between NB-domains is about 30 Å.  
 
The protein is “open” to the inside of the cell membrane leaflet and also to the cytosol 
(Rosenberg et al. 2005, Aller et al. 2009, Jin et al. 2012). The binding of P-gp substrates 
is assumed to happen in the “binding cavity” left between two halves of protein (Aller et 
al. 2009, Jin et al. 2012). Aller et al. (2009) suggested that the crystallized form of 
mouse P-gp is in the substrate binding state and can open even wider than illustrated in 
the crystallized form. Large size of the protein and shape of the “binding cavity” 
enables binding of large molecules or more than one molecule at the same time which 
could partly explain why P-gp has a wide selection of substrates and ability to bind 
several molecules at the same time.  
 
Figure 3. X-ray crystal structure of mouse P-gp-protein. A binding cavity is formed 
between the two halves (presented with blue and yellow) of the protein. NBD is 
nucleotide binding domain and TM is transmembrane domain (modified from Aller et 
al. 2009). 
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The nature of amino acid residues predicts the ability of molecules with variable 
hydrophobicity to interact with the protein.  Most of the amino-acids facing inside in the 
upper part of the cavity are hydrophobic or aromatic which makes the binding cavity 
hydrophobic and easier for lipophilic molecules to get access to (Aller et al. 2009). 
However in the lower part of the cavity there are also hydrophilic residues and therefore 
also polar compounds can get inside the cavity. Loo et al. (2004) further suggested that 
there is an aqueous environment in the binding cavity. The group demonstrated that 
cysteines in TM5 can interact with charged compounds (thiol-reactive compounds 
MTSES and MTSET). They proposed that hydrophobic substrates could be hydrolyzed 
prior entering the cavity and hence stabilized to stay in the cavity.  
 
The amino acid structure of mouse P-gp is 87 % and C. elegans PGP-1 46 % similar to 
human P-gp thus the structure of human P-gp is probably different from the structures 
of the two species. At least two trans-membrane helices of mouse P-gp are different 
compared to human P-gp and ATPase activity of C. elegans PGP-1 was stimulated by 
only part of the human P-gp substrates (Jin et al. 2012, Li et al. 2013). On the other 
hand according to Li et al. (2013) the sequence identity of amino acids in drug pathway 
is rather high between mouse and human P-gp (96 %) while C.elegans sequence 
identity of PGP-1 and human P-gp is much lower (13 %). Thus the crystal structure of 
mouse P-gp serves as a good model for the P-gp fine structure until the crystal structure 
of human P-gp is determined. 
 
2.2 Ligand binding sites 
 
Relevant areas for drug binding have been studied by inducing mutations in certain 
amino acid residues. Ambudcar et al. (1999) reviewed extensively the effect of mutation 
in different trans-membrane domains (TM), extracellular loops (EC), intracellular loops 
(IC), and nucleotide binding domains (NBD) on substrate activity. Mutation in several 
human P-gp TM-helices (Table 1.) as well as in mouse TM11 had an effect on substrate 
binding. Also mutation in EC1, IC1, and 4, and N-NBD had an effect on P-gp function. 
However it must be noted that mutation can affect the protein function also by changing 
the shape of the protein. According to more specific method based on direct binding of 
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thiol-analogues with TM cysteine residues the binding pocket of human P-gp is at least 
partly formed from TMs 1, 6, 7, and 12 (Table 1) (and Clarkeal. 2006a, Loo et al. 
2006b, Loo and Clarke 1997).  
 
Table 1. Essential transmembrane domains (TMs) for substrate binding of human P-
glycoprotein determined with mutation analysis and thiol-analogue binding methods. 
Analysis method TMs (human P-gp) 
Mutation analysis
1 
1, 4, 5, 6, 10, 12 
Thiol-analogues
2 
1, 6, 7, 12 
1
 Ambudcar et al. 1999  
2
 Loo et al. 2006a, Loo et al. 2006b, Loo and Clarke 1997 
 
A protein is a dynamic complex which is why it is difficult to separate the most 
important TM-helices. However TMs 6 and 12 are the most frequently considered as 
essential for substrate-protein interaction. Mutation in TM6 or nearby TM6 of humans 
P-gp can alter the effect of P-gp on its substrates (vinblastine, colchicine, doxorubicin 
and actinomycin) and change the activity of a P-gp inhibiting monoclonal antibody 
UIC2 (Loo and Clarke 1994a, Zhou et al. 1999). Also in crystal structure complex of 
mouse P-gp and a P-gp inhibitor QZ59 (Figure 4.) the compound is located in the 
intracellular side of the protein, close to the TM6 and TM12 (Aller et al 2009). Two 
tested isomers (QZ59-SSS and QZ59-RRR) had some differences in orientation and 
location of the compounds in the cavity but for example the isopropyl groups of the 
both molecules were close to TM 12 (and 9).  
 
The crystal structures of both mouse and C.elegans protein indicate that protein α-
helices are at the same angle with each other except for one pair, TMs 6 and 12 and 
TMs 10 and 12, respectively (Aller et al 2009, Jin et al. 2012). Also Rosenberg et al. 
(2005) found that in 3D-structure (obtained from 2D crystals) of Chinese hamster P-gp 
there are non-organized helices TM 6 and TM 12. More open helixes have readily 
interactions with possible ligands and other surrounding molecules thus they probably 
participate in binding of ligands and directing the substrates to the trans-membrane 
cavity (Rosenberg et al. 2005, Jin et al. 2012). This also confirms importance of TMs 6 
and 12. 
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Figure 4. Crystal structure of mouse P-glycoprotein binding cavity hosting a P-gp 
inhibitor QZ59-RRR A) from plane and B) from above. The compound is located in the 
intracellular side of the protein, close to the transmembrane domains 6 and 12 (modified 
from Aller et al 2009). 
 
Having many of the TM helices interacting with substrates indicates a high binding 
potential. At least two separate binding sites for P-gp substrates have been proposed by 
several research groups (Dey et al. 1997, Shapiro and Ling 1997a, Shapiro and Ling 
1997b, Shapiro and Ling 1998, Loo et al. 2003c, Wang et al. 2003). Shapiro and Ling 
(1997b) demonstrated that fluorescent agents Hoechst 3342 and rhodamine 123 
stimulated each other’s P-gp mediated transport and were transported at the same time 
in Chinese hamster ovary cell vesicles which indicates that molecules bind to different 
binding places. The two binding sites were named R- (rhodamine 123) and H- (Hoechst 
33342) site according their substrates. It was also demonstrated that mutation in one 
TM-helix (TM5, which is close to binding site of verapamil) decreased ATPase activity 
stimulated by verapamil and vinblastine but there was no effect on activation by 
rhodamine B and colchicine indicating that the latter molecules bind to different site 
than verapamil and vinblastine (Loo et al. 2004). Recently the successful co-
crystallization of mouse P-gp with two substrate (QZ59-SSS) molecules further 
demonstrated that P-gp can in fact occupy at least two molecules  at the same time 
(Figure 5) (Aller et al. 2009).  
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Figure 5. Mouse P-gp can host two molecules of a P-glycoprotein substrate QZ59-SSS 
at the same time in the internal cavity of the protein (modified from Aller et al 2009). 
 
With the help of specific R- and H-site substrates it was demonstrated that the two 
binding sites have different substrate selectivity. Transport rate of Hoechst 33342 and 
Rhodamine 123 was affected in different manner by P-gp substrates (Shapiro and Ling 
1997b). The same molecules that increased the transport rate of rhodamine 123 in 
concentration dependent manner in P-gp-expressing vesicles decreased the transport 
rate of Hoechst 33342. Thus it seems that one part of the molecules bound to the R-site 
and other part bound to the H-site.  Another option is that there are even more than two 
binding sites (Shapiro et al. 1999, Martin et al. 2000). Shapiro and coworkers 
demonstrated that the transport rate of Hoechst 33342 was stimulated additively in 
plasma membrane vesicles if it was administered with both Rhodamine 123 and 
prazosin or progesterone. On the other hand simultaneous administration of prazosin 
and Hoechst 33342 did not stimulate transport rate of rhodamine 123, but seemed to 
interfere the additive effect of Hoechst 33342. The group suggested that prazosin and 
progesterone bind to third, allosteric binding site which has different kind of effect on 
H- and R-site. The function of P-glycoprotein binding sites based on specific H- and R-
sites is concluded in Figure 6. Martin et al. (2000) further suggested that P-gp could 
have even four different binding sites for ligands, of which one acts solely as a 
regulatory site whereas the H-site has both regulatory and transport function. 
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Figure 6. P-glycoprotein has two binding sites (H- and R-site) which can function 
simultaneously and additively and an allosteric binding site A) Hoechst 33342 binds to 
H-site and Rhodamine 123 to the R-site to be transported. B) When both molecules are 
present they increase each other’s transport rate C) Binding to allosteric site increases 
transport of Hoechst 33342. Arrow indicates transport rate. 
 
3 FUNCTION OF P-GLYCOPROTEIN 
 
3.1 Binding of ATP 
 
It is clear that ATP hydrolysis is required for transporting P-gp substrates (Al-Shawi 
and Senior 1993, Kimura et al. 2004). As mentioned before P-gp has two nucleotide 
binding sites which are hydrophilic and located in cytosol (Rosenberg et al. 2005). 
Mutation in NB-domain of at least N-terminal affects the function of the protein (Hoof 
et al. 1994). The NB-domains have also several motifs, (such as Walker A, Walker B, 
LSGGQ/ABC signature motif) which participate in ATP hydrolysis and interact with 
ATP (Walker et al. 1982, Hennessy and Spears 2007). Both NBs have been 
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demonstrated to be active yet dependent on each other (Urbatsch et al. 1995). In early 
studies it was found that N-terminal NB site hydrolyzed ATP without interaction with 
the C-terminal (Shimabuku et al. 1992). Later studies however implicate that both ATP 
molecules have role in the catalytic cascade which causes transport of substrate (Dey et 
al. 1997, Sauna et al. 2007, Wang et al. 2003). 
 
P-gp has been proposed to act like a two-cylinder engine whose two ATP binding sites 
hydrolyses ATP molecules and two drug binding sites transports substrates by turns 
(van Veen et al. 2000). Several studies indicate that there are some conformational 
changes in P-gp structure after ATP is bound. According to theory of catalytic cycle of 
ATP hydrolysis, nucleotide binding domains are dimerized by the effect of ATP (Sauna 
et al. 2007) (Figure 7.). While ATP catalyzes dimerization, ADP causes dissociation of 
dimer. ATP binds to both nucleotide binding sites but is hydrolyzed at different time at 
the two binding sites. This cycle causes conformational change of the P-gp molecule 
and may alter the affinity of the substrates to P-gp.  
 
 
Figure 7. Two ATP molecules catalyze dimerization of P-glycoprotein by turns and 
causes conformational change in P-glycoprotein structure. One of two ATP molecules is 
occluded to ATP site (step I) and hydrolyzed to ADP (step II) which causes electrostatic 
repulsion and simultaneous release of ADP and occlusion of ATP to ATP site 2 (step 
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III). The cycle (steps I-III) is repeated in APT site 2 (steps IV-VI) (modified from Sauna 
et al. 2007) 
 
It has been proposed that substrate affinity to two binding sites can alter from low to 
high affinity state (Dey et al. 1997, Wang et al. 2003). Dey et al. (1997) proposed that 
the two binding sites of P-gp are “ON” (C-terminal) and “OFF” (N-terminal) site. They 
suggest that substrates bind more favorable to the “ON” site and moving from the 
“ON”-site to the “OFF”-site demands the energy from ATP hydrolysis and leads to 
transport of the substrates. The catalytic cycle of P-gp is explained more closely in 
Figure 8. Replacement of Pi in Pg-MgADP complex with vanadate (vi) was able to 
stabilize the complex and prevent substrates from binding to P-gp implicating that both 
ATP molecules are needed for the transport cycle. This finding and theory of Sauna et 
al. (2007) confirms that both ATP molecules are needed for the transport cycle. 
 
Figure 8. In the catalytic cycle of P-glycoprotein binding sites alter from high to low 
affinity in different phases of ATP hydrolysis. Squares represent TM (transmembrane) 
domains, circles ATP-binding sites and ovals substrate interacting sites. Step I: no drug 
is bound. Step II: drug can bind to the “ON”-site without demanding energy from ATP. 
Step III: affinity of substrate to the “ON”-site is decreased in consequence of 
conformational change catalyzed by ATP-hydrolysis and a drug moves to the “OFF”-
site. Step IV: drug is released from the “OFF”-site to the exterior of the cell (Adapted 
from Dey et al. 1997). 
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3.2 Transport mechanism  
 
The mechanism by which P-gp recognizes and transports its substrates has puzzled 
researchers and there are at least three different theories for the mechanism of function 
(Ambukar et al. 1999, Kimura et al. 2004, Sharom et al. 2005). P-gp has been proposed 
to recognize the substrates directly from membrane because of the lipophilic nature of 
the substrates (Shapiro and Ling, 1997a). Both H- and R-site substrates have been 
demonstrated to be transported directly from the membrane cytoplasmic leaflet to the 
extracellular medium (Shapiro and Ling, 1997a, Shapiro and Ling 1998). Lipophilic 
drugs can easily dissolve in membranes and may occur with higher concentrations in 
membranes than in aqueous cytoplasm or extracellular material which also supports the 
theory that substrates are transported directly from the membrane.  
 
The first theory was that P-gp acts as a “hydrophobic vacuum-cleaner” which transports 
the substrates immediately when they enter the membrane (Raviv et al. 1990). 
According to this theory transport is more dependent on the lipophilic nature of 
substrate than selective binding of substrate. As mentioned before the common opinion 
is that P-gp substrates are bound by TM-domains (Ambudcar et al. 1999, Shapiro et al. 
2005). Substrates could get inside P-gp and “vacuum-cleaned” from the “gates” which 
are left between the two halves of the protein in the membrane (Figure 9). The gateway 
for substrates have been suggested to form from TMs 2, 11, 5, and 8 in human P-gp 
(Loo and Clarke 2005) and TMs 4, 6, 10 and 12 in mouse P-gp (Aller et al. 2009). 
 
 
Figure 9. TMs 5 and 8 (A) and TMs 2 and 11(B) form gateway for drug enter to the 
binding cavity of human P-glycoprotein (Modified from Loo and Clarke 2005) 
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Efficient transport and hydrophilic nature of substrates have been explained also with 
another theory. P-gp has been proposed to act as a “flippase” and transport its substrates 
from the inner leaflet of cell membrane to the outer leaflet of the cell membrane in the 
same manner its “flips” short chain phospholipids across the lipid bilayer (Higgins and 
Gottesman 1992, Romsicki and Sharom 2001). It has been proven that P-gp can act as a 
flippase and translocate hydrophobic fluorescent labeled glycosphingolipids (GSL), 
sphingomyelin (SM) and cholesterol in the lipid bilayer from one side to another 
(Garriques et al. 2002, Eckford and Sharom 2005). Like transport of ligands, flipping of 
phospholipids required presence of ATP and is inhibited by the effect of vanadate which 
traps P-gp into a transition stage (Romsicki and Sharom 2001, Eckford and Sharom 
2005). With the help of FRETT (fluorescence resonance energy transfer), the position 
of P-gp substrate LDS-751 in the membrane has been demonstrated to be in the 
cytoplasmic leaflet of the membrane (close to NBs) from where the flipping happens 
(Lugo and Sharom 2005). In addition P-gp substrates and modulators, such as 
cyclosporine, verapamil, vinblastine, and PSC-833, inhibited flipping of phospholipids 
thus flippase function and ligand binding seems to occur at the same site and may be 
competitive (Romsicki and Sharom 2001). Johnstone and coworkers (2000) proposed 
that flipping is a fast process whereas the release of substrate from the inner leaflet is 
slower which explains the high transport rate of P-gp. 
 
Substrate binding (along with binding of ATP) to the protein is the first stage of the 
transport mechanism but another question is what happens after that. Several theories 
suggest that the substrate is transported in consequence of conformational change of the 
protein (Loo and Clarke 2002, Loo et al. 2003a, Aller et al. 2009). This can be 
concluded also from ATP binding theories presented above which suggest that shape of 
the protein changes as a consequence of ATP binding and hydrolysis. An “induced fit” 
mechanism was introduced which proposes that binding of substrate changes the 
conformation of P-gp which causes the drug transport out of the cell (Loo and Clarke 
2002, Loo et al. 2003a).  
 
Already in 1992 Bruggeman and coworkers suggested that two halves approach each 
other in order to bind a substrate. Aller and coworkers (2009) suggested that P-gp is 
14 
 
open to cytosol in substrate binding state (Figure 10A). After ATP is bound to the 
NBDs the conformation of protein is changed to the form which is open to the 
extracellular space (Figure 10B). Conformation change could be result of different 
cross-linking between TM-domains (Loo et al. 2003a). Cross-linking between TM6 and 
TM 11 or TM 12 was induced by the effect of P-gp substrates. It was proposed that the 
conformational change could create a funnel for substrates to move to the other side. 
The effect of the substrates varied in creating slightly differing cross-links which could 
be result from binding to different sites. The conformational change of the protein could 
also create new binding sites for substrates which could explain the great variety of 
ligands.  
 
 
Figure 10. P-glycoprotein is open to cytosol in substrate binding state and after binding 
of ATP changes the conformation to form which is open to the extracellular space 
(adapted from Aller et al. 2009) 
 
Different P-gp substrate transport mechanisms are demonstrated in Figure 11. Theory of 
hydrophobic vacuum cleaner and induced fit are in the same line with each other. The 
substrate is taken inside the cell by passive absorption (or active transport) and from 
cytosol to the binding site of P-gp. Alternatively P-gp interacts with the substrate 
already in lipid bilayer and substrate binds to the binding site. The substrate binding 
changes the protein conformation which leads to the substrate transport outside the cell. 
However it is unclear if a flippase mechanism is entirely separate mechanism or does it 
also require conformational change. 
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Figure 11. Transport mechanisms of P-glycoprotein (P-gp) substrates A) Induced fit. 
Substrate binds to the protein and is releases to the extracellular space after 
conformational change of P-gp B) Hydrophobic vacuum cleaner. Substrate is absorbed 
to the cell membrane and immediately taken in by P-gp and transported (in the 
consequence of induced fit) C) Substrate is flipped from the inner membrane leaflet to 
the outer leaflet by P-gp  
 
3.3 Mechanism of inhibition 
 
Understanding the mechanism of inhibition is of great interest because of the possibility 
of finding chemo-sensitizers which could improve the efficacy of cytotoxic agents 
(Ambudcar et al. 1999, Hennessy and Spears 2007). Binding of several substrates on P-
gp have been demonstrated to be co-operative, competitive or non-competitive 
(Acharya et al. 2006, Garrigos et al. 1997, Litman et al. 1997, Shapiro and Ling 1997a; 
Shapiro and Ling 1997b; Shapiro and Ling 1998). Competitive inhibitors can inhibit the 
interaction of another ligand with protein by binding to the same binding site or 
alternatively to the distinct allosteric binding site (Garrigos et al. 1997). Non-
competitive inhibitors bind to distinct sites which do not communicate with each other 
and therefore synergetic effect is possible. For instance vinblastine and cyclosporine 
inhibited ATPase activity of verapamil or progesterone in competitive manner in P-gp 
expressing cells whereas verapamil and progesterone had co-operative effect on ATPase 
activity (Garrigos et al. 1997, Litman et al. 1997). Having several binding sites means 
that substrates and inhibitors can bind to different sites which explains why different 
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drugs affect in different manner to P-gp substrate transport. In addition the inhibition of 
substrate transport could happen by preventing the substrate-binding place interaction 
but also by interfering the binding or reaction of ATP (Ambudcar et al. 1999). 
 
The complexity of inhibition mechanisms makes it difficult to predict the significance 
of drug-drug interactions. When the efflux of P-gp substrates and inhibitors was studied 
in MDCKII-MDR1 cells, P-gp was demonstrated to transport both inhibitor and 
substrate simultaneously (Acharya et al. 2006). The presence of inhibitor or another 
substrate did not affect the efflux of substrate at low concentration which can be result 
from binding to separate places. On the other hand, when the authors fitted rate 
constants to a model expecting that substrates and inhibitors compete for one binding 
site, substrates fitted well with high inhibitor/substrate concentrations. The authors 
proposed that both substrates and inhibitors can bind to the same binding place because 
the competitive binding occurs when concentration of either rises. According to these 
studies it seems that there are no specific inhibiting binding sites but inhibition is rather 
dependent on the structure of certain molecules at the same site. This means that every 
drug pair should be studied to find out if inhibition occurs. 
 
 
4 REGULATION OF P-GLYCOPROTEIN 
 
4.1 Factors effecting P-glycoprotein expression 
 
Not only inhibition but also induction of P-gp can cause drug-drug interactions which is 
why it is important to understand the mechanism which leads to increased protein 
levels. The regulation of P-gp expression is very complex and can be affected by both 
environmental stimulus and transcriptional factors (Hennessy and Spears 2007). 
Especially mechanisms by which chemotherapeutic agents stimulate the expression of 
P-gp have been of great interest. The phase of the cell proliferation may have some 
influence on P-gp expression and multidrug resistance (Wartenberg et al. 2002). The 
group of Wartenberg (2002) studied if the inhibition of the cell cycle and cell cycle 
17 
 
inhibitors affect P-gp expression and multi drug resistance. They demonstrated that the 
amount of P-gp was increased when largest number of cells was in the resting phase.  
 
It is not clear whether P-gp induction is mediated in receptor level or in gene level 
(Hennessy and Spears 2007). There is also evidence that some chemotherapeutic drugs 
can cause epigenetic changes in P-gp coding (MDR1) gene promoter and therefore alter 
the phenotype of P-gp (Baker et al. 2005).  This means that drug resistance is not caused 
only by increasing transcription of gene but also in the way transcription is regulated. 
Epigenetic changes could also explain the inter-individual differences in P-gp mediated 
efflux and gene polymorphism (Lown et al 1997).  
 
4.2 Nuclear receptors  
 
Nuclear receptors pregnane X (PXR) (also known as SXR, NR1I2) and constitutive 
active receptor (CAR) (NR1I3) have been connected to expression of several 
metabolizing enzymes (CYP) and transporters (such as P-gp, Mpr2, BCRP) (Dussault et 
al. 2001, Luo et al. 2002, Zhang et al. 2007, Johnson et al. 2008, Wang et al 2010). 
Being an orphan receptor, PXR forms a heterodimer with Retinoid X receptor (RXR) 
and RXR ligands (retinoids) can activate PXR (human or rabbit)-RXR heterodimer thus 
also involvement of RXR in regulation of P-gp expression is likely (Jones et al. 2000, 
Sulová et al. 2008). The activation mechanism of nuclear receptors is presented in 
Figure 12. When a ligand is not present, receptor is in multi-protein complex in 
cytoplasm (Kliewer et al. 1998, Timsit and Negishi 2007, Slosky et al. 2013). When a 
ligand appears the receptor is released from the complex and transports into the nucleus. 
In the nucleus it forms heterodimer with RXR and induces gene transcription.  
 
In consequence of receptor activation by P-gp inducer the expression of mRNA of P-gp 
and therefore expression of P-gp increases (Lowes et al. 2010). The increased P-gp 
expression increases the efflux of P-gp substrate and therefore smaller amount of drug 
can get to the binding place. Some drugs such as paclitaxel can act as their own efflux 
inducers and therefore prevent their own therapeutic effect (Synold et al. 2001). 
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Figure 12. Activation mechanism of nuclear receptors. Pregnane X receptor (PXR) or 
constitutive active receptor (CAR) receptors bind their substrates in the cytosol, 
translocate to the cell nucleus and form a heterodimer with RXR. The dimer causes 
induction of gene expression and protein production.  
 
PXR and CAR receptor expression in the body is somewhat the same as P-gp 
expression which also implicates that nuclear receptors are involved in P-gp regulation. 
mRNA of PXR was expressed in high levels in the liver and intestine and with lower 
levels in the kidney, stomach, ovary, and uterus of an adult mouse (Kliewer et al. 1998, 
Masuyama et al. 2001). In human tissue mRNA of PXR –receptor was expressed at 
high levels in the liver, small intestine, and colon and lower levels in other tissues 
(Nishimura et al. 2004). CAR-receptor levels were the highest in the liver and the 
kidney. PXR is also expressed in tumor cells where P-gp expression is typically high 
(Synold et al. 2001).  
 
4.3 Pregnane X receptor 
 
According to the present knowledge nuclear receptor pregnane X (PXR) is an important 
link in P-gp regulation because known P-gp inducers such as rifampicin, vinblastine and 
carbamazepine can activate the PXR receptor (Geick et al. 2001, Wentworth et al. 2000, 
Synold et al. 2001, Luo et al. 2002, Sulová et al. 2008). The mechanism of receptor 
involvement in P-gp regulation has been studied with P-gp expressing cancer cell lines 
such as LS180 and LS174T (both from human colon carcinoma) and L1210/VCR 
19 
 
(mouse leukemia) and with different PXR transfected cell lines (such as CV-1) (Geick 
et al. 2001, Sulová et al. 2008, Harmsen et al. 2012). Multidrug resistance by P-gp 
overexpression can be induced in L1210 cells with doxorubicin and vincristine and 
overruled with P-gp-inhibitors (Boháčová et al. 2006). Recently it was suggested that 
that quickly developing drug resistance is mediated by PXR-receptors because tyrosine 
kinase inhibitors (TKIs) induced P-gp in LS180 cells (Harmsen et al. 2012).  Just in last 
year it was shown that PXR is involved in regulating P-gp expression also in brain-
blood barrier (Chan et al. 2013). When studied with brain microdialysis scientists 
showed that PXR ligand and P-gp inducer dexamethasone decreased the concentration 
of P-gp substrate quinidine in brains and up-regulated P-gp expression.  
 
Studying the effect of St. John’s wort and its ingredients to expression of PXR proved 
that P-gp inductive effect is caused by direct interaction of inducer and receptor (Moore 
et al. 2000, Wentworth et al. 2000). According to present knowledge St. John’s wort has 
an inductive effect on intestinal P-gp along with CYP3A4 (Schwarz et al. 2007).  Moore 
et al. (2000) demonstrated that hyperforin, one of the active ingredients of St. John’s 
wort activated PXR-receptor in CV-1(human hepatocyte). When studied with 
competition binding it was demonstrated that hyperforin competed with radioactive 
PXR ligand (SR12813) which proves that hyperforin activates PXR by direct binding to 
the PXR. Also Wentworth et al. (2000) demonstrated 5-fold difference in activity of 
PXR with and without St. John’s Wort in JEG-3 cells and that in fact, the effect was 
mediated by binding to the ligand binding domain (LBD) of PXR.  
 
4.4 Constitutive active receptor  
 
Another nuclear receptor, constitutive active receptor (CAR) has been suggested to 
mediate P-gp induction (Burk et al. 2005, Johnson et al. 2008, Wang et al 2010, Chan et 
al. 2011, Slosky et al. 2013).  Burk et al. (2005) demonstrated that CAR was able to 
bind to the same gene motif (DR4(I)) of P-gp than PXR. Also when studied in human 
brain microvessel endothelial cell culture (hCMEC/D3) the expression of both P-gp and 
P-gp mRNA increased after hCAR and hPXR activation (Chan et al. 2011). 
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P-gp expression has been connected to the activation of CAR receptor in BBB with 
rodents (Wang et al 2010, Slosky et al. 2013). The expression of P-gp can be stimulated 
with CAR ligands (TCPOBOP, phenobarbital) and expression of P-gp mRNA correlates 
with CAR activation (Wang et al. 2010). Slosky et al. (2013) demonstrated in vivo with 
rats that paracetamol mediated P-gp expression increase in BBB was inhibited by CAR 
inhibitors (OA and Act D which inhibit translocation of CAR to the nucleus and 
transcriptional effect, respectively). CAR expression in the nuclear compared to cytosol 
was measured to demonstrate CAR activation.   
 
It seems evident that P-gp gene regulation is mediated by nuclear receptors. However, 
the mechanism which leads to gene transcription of certain protein is unclear. As stated 
before PXR and CAR mediate up-regulation of several transporters and enzymes. 
Studies demonstrate that enzymes and transporters, such as CYP3A4 and P-gp can have 
overlapping substrates and interplay (Luo et al. 2002). This is probably at least partly 
caused by a common regulation system. However Burk et al. (2005) found that instead 
of dimers, CAR monomers interacted with P-gp gene. The group suggested that this 
could separate CAR mediated regulation of P-gp and CYP3A4 from each other. 
Substrate selection of PXR and CAR is also partially overlapping (Moore et al. 2002). 
There was however much fewer compounds that activated CAR receptors which means 
that inductions is more likely mediated by PXR rather than CAR. 
 
 
5 P-GLYCOPROTEIN LIGANDS  
 
5.1 Recognizing molecules interacting with P-glycoprotein 
 
Some molecules interact with P-gp and are transported (substrates), some inhibit the 
function P-gp (inhibitors), and some act as both inhibitors and substrates. In addition 
there are inducers which improve the P-gp function. P-gp ligands can be studied with 
several in vivo and in vitro assays (Didziapetris et al. 2003). In in vivo assays utilize P-
gp transgenic and P-gp gene knockout rodents such as mice and rats. In vitro assays 
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include transport assays, membrane accumulation assays and ATPase assay. In addition 
cancer lines are used to study the ability of study compounds to increase the effect of 
cytotoxic agents (Zamora et al. 1988). The ATPase assay is based on the fact that P-gp 
efflux is dependent on ATP hydrolysis thus the ATPase activity of the test drug is 
measured (Sarkadi et al. 1992). Cell based assays use cell lines that express P-gp (such 
as Caco-2) and P-gp gene transfected cell lines (such as MDCK and Chinese hamster 
ovary cell line). The membrane accumulation method utilizes human P-gp transfected 
membrane (Aanismaa 2007). MDCKII-MDR1 transport cell assay and P-gp membrane 
accumulation assay are used and explained more in detail in experimental part.  More 
direct study methods are functional analysis with the help of photo-affinity labeling or 
direct binding studies with thiol cross-linking agents (Bruggeman et al. 1992, Ecker et 
al. 2002). These methods have been utilized especially when the binding sites of the 
protein have been studied. 
 
The study methods are mostly based on interaction between recognized substrates or 
modulators. FDA offers a list of acceptable P-gp substrates and inhibitors for in vitro 
studies (Table 2). One problem, however is that some compounds can act as both a 
substrate and an inhibitor (such as verapamil) which complicate interpretation of the 
results (Didziapetris et al. 2003, Srivalli and Lakshmi 2012). Also many molecules are 
substrates or modulators of more than one transporter (such as cyclosporine A) (Rebello 
et al. 2011). 
 
Table 2 Acceptable P-gp substrates and inhibitors for in vitro studies according to FDA 
(2012) 
In vitro substrates In vitro inhibitors 
digoxin cyclosporine A 
loperamide elacridar (GF120918, GG918) 
quinidine ketoconazole 
talinolol LY335979 
vinblastine nelfinavir 
 quinidine 
 reserpine 
 ritonavir 
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 saquinavir 
 tacrolimus 
 valspodar (PSC833) 
 verapamil 
 
Computational methods are used extensively for substrate screening. The substrates can 
be recognized by docking experiments where different molecules are fitted in to the 
binding pocket of the protein to find out which molecules most likely. Alternatively, 
substrate screening can be based on known ligands and their structure (Matsson and 
Artursson 2013). 
 
Now that the crystal structure of mouse P-gp is known it can be utilized to predict 
structure of human P-gp (Chen et al. 2012). In silico quantitative structure-activity 
relationship (QSAR) assay have been used in recognizing P-gp ligands with variable 
results (Sharom et al. 2005). Often in silico methods are based on the experimental data 
set result which defines the P-gp substrates and modulators. The largest dataset included 
1273 molecules from which 797 were P-gp inhibitors (Chen et al. 2011). The data sets 
however, are a result of variable study methods, laboratories and definers of the affinity, 
thus making incisive predictions based on them is challenging (Stouch and 
Gudmundsson 2002).  
 
P-gp ligand specificity is affected by many factors such as molecular weight (MW), 
logP, number of aromatic groups, number and strength of hydrogen accepting groups 
(~number of O and N atoms), acidity, surface area, and 2/3D pharmacophore 
(Didziapetris et al. 2003). Some factors such as logP and hydrophobicity seem to be 
more important to inhibitors than to substrates but finding distinctive features between 
substrates and modulators is very challenging.  
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5.2 Is there a typical P-glycoprotein interacting molecule? 
 
5.2.1 Physicochemical properties of drug and rule of four 
 
Didziapetris et al. (2003) studied P-gp substrate specificity with a stepwise 
classification structure–activity relationship (C-SAR) method using 1000 compounds. 
The group used compound size, hydrogen bond accepting ability (eg. sum of N and O 
atoms) and ionization as defining factors. They found that molecules follow loosely a 
“rule of fours” (related to Lipinski’s rule of five) thus the compounds which have sum 
of N and O atoms less than 8, molecular mass more than 400 and acidic pKa less than 4 
are most likely P-gp substrates. The group noted that a basic compound with large MW 
and high H-bond accepting is the most probable substrate.  
 
The optimal size of less than 400 Da defined for P-gp substrates by the “rule of four” is 
controversy because according to the common view P-gp substrates have wide 
dispersion in molecular weights the rule of fours (Srivalli and Lakshmi 2012). On the 
other hand, “rule of fours” is in agreement with previous studies about the importance 
of N- and O-atoms. Need for the presence of nitrogen atom has been mentioned in 
several other studies and some studies suggests that the sum of the O and N-atoms is 
important like “rule of fours” states (Tang-Wai et al. 1993, Klopman et al. 1997, Pajeva 
and Wiese 2002, Cianchetta et al. 2005).  
 
According to “rule of fours” hydrophobicity and number of aromatic groups do not 
influence on substrate specificity. This is in agreement with the results El Ela and 
coworkers (2004) obtained when they studied structure activity of 15 psychoactive 
compounds. With psychoactive compounds logP ranging from 1.56 to 4.5 there was no 
correlation between logP and affinity to P-gp. However in one previous study it was 
demonstrated that molecule with logP higher than -1 can be P-gp inhibitor (Dellinger et 
al. 1992). This could be reason why there was no difference seen in the study of el Ela 
et al. (2004) with rather hydrophilic compound group. Also number of studied 
compounds was very low which is why the results can not be generalized. 
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According to the nature of binding cavity the most likely binding force between 
substrate and cavity is π-π binding thus the lipophilicity would be expected to affect the 
binding affinity (Lugo and Sharom 2005). Klopman et al. (1997) listed logP as an 
important factor for inhibitory effect. Also in another early study lipid soluble (logP ≥ 
1) compounds in physiological pH were able to increase vinca-alcaloid cytotoxicity 
while almost all of the water soluble compounds were not (Zamora et al. 1988). This 
suggests that in order to compete from binding to P-gp with vinca-alcaloids the 
molecule needs to be lipophilic. However also in the mentioned study the number of 
compounds was low (about 20). Therefore according to studies made so far the 
lipophilicity of P-gp interacting molecule seems to be important in some compound 
groups but it can not be said to be discriminatory factor. 
 
5.2.2 Spatial structure and hydrogen bonding 
 
The riddle has been approached by investigating the body structure of ligands. Several 
studies show that the position of hydrogen bonding groups is an important descriptive 
factor for P-gp affinity (Seelig 1998, Seelig and Landwojtowicz 2000, Didziapetris et al. 
2003, Pajeva and Wiese 2002, Cianchetta et al. 2005). Seelig (1998) proposed that P-gp 
substrate has two (type I substrate) or three (type II substrate) electron donor groups 
which have designated separation between each other. Type I pharmacophore has 2.5 ± 
0.3 Å separation between two electron donor groups and type II has 4.6 ± 0.6 Å 
separation between two outer electron donor groups or alternatively 2.5 ± 0.3 Å 
separation between all three groups. Based on testing of 100 compounds it was 
concluded that when the number and “strength” of hydrogen bonding groups increased 
the probability of drug being a P-gp substrate or inducer increased. Also Pajeva and 
Wiese (2002) found that increasing number of wide spread hydrophobic groups are 
important for P-gp interacting compound.  
 
Type I and II molecules were further tested by determining the dependency of transport 
rate with air-water coefficient (Kaw) and critical micelle concentration (CMC) (Seelig 
and Landwojtowicz 2000). Kaw and Km (Michaelis-menten constant) were linearly 
dependent and the higher the amount and strength of hydrogen bond donors (HD) in the 
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compound structure the lower was the transport rate (Vmax) obtained from ATPase 
assay. The group proposed that hydrogen bond formation helps ligands to interact with 
P-gp but because of them the partitioning to the lipid membrane is the rate limiting step 
which would explain the lower transport rate.  
 
Cianchetta et al. (2005) demonstrated that from two defining factors, GRIND (Grid 
independent descriptors) pharmacophore and physicochemical properties, the first one 
had clearly higher correlation with inhibitory potency. This suggests that the core spatial 
structure is more important descriptor than simply physicochemical properties. 
Inhibitory effect of 129 compounds was first studied with calcein-AM assay and then a 
3D QSAR analysis was performed. Based on their findings they suggested that the 
ligand recognition happens by two hydrophobic and two hydrogen-bond acceptor 
groups which have 16.5 Å and 11.5 Å separations, respectively.  
 
Recently it was demonstrated that combination of rigid and flexible groups in ligand 
structure causes good binding affinity (Orlandi et al. 2012). N,N-bis(cyclohexanol) 
amine scaffold gives this kind of structure to a series of newly developed P-gp 
inhibitors thus the group suggested that this scaffold structure can be exploited in 
designing of P-gp regulators (Martelli et al. 2009). The structure of these new 
compounds is different from previous P-gp inhibitors in many ways but they have 
several hydrogen bonding groups. The base structure of the compounds resembles the 
“ideal” structure Klopman and coworkers suggested already in 1997 for anti-cancer 
drugs based on the basic structure of paclitaxel. Ekins et al. (2002) produced a 3D 
pharmacophore for P-gp inhibitor based on 16 verapamil metabolites which have 
inhibitory effect on P-gp (Figure 13). Important features in the structure were one 
aromatic ring, two hydrophobic areas, hydrogen bond accepting group and wide spread 
form.  
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Figure 13. Pharmacophore (colored balls, green for hydrogen bond acceptor, orange for 
aromatic area and cyan for hydrophobic area) for P-gp inhibitor created in based on 
verapamil metabolites and molecule Lu-47474 (black, white and red lines) fitted to the 
pharmacophore (obtained from Ekins et al. 2002) 
 
5.3 Therapeutic groups 
 
Most commonly P-gp substrate or modulator belongs to the therapeutic group of 
anticancer and cytotoxic drugs (Gottesman and Pastan 1993, Ambudcar et al. 1999, 
Linardi et al. 2006, Hennessy and Spears 2007). There are several P-gp interacting 
drugs also among immunosuppressive drugs, steroids, HIV protease inhibitors, 
antimicrobial, and cardiac drugs and in many more groups. Examples of P-gp ligands 
from different therapeutic groups are presented in Table 3. Also lipids, several fruits 
herbs and natural product constituents can interact with P-gp (Srivalli and Lakshmi 
2012). In the experimental part P-gp mediated transport of β-adrenoceptor antagonists 
celiprolol and talinolol, H1 histamine receptor antagonists fexofenadine and cardiac 
drug aliskiren are investigated. 
 
Table 3. Examples of P-gp substrates and inhibitors from different therapeutic groups 
(Adapted from Linardi et al. 2006 and Srivalli and Lakshmi 2012) 
Substrates 
Antiacids Cimetidine, Ranitide 
Antibiotics Erytromycin, Tetracycline, Rifampicin, Levofloxacin 
Antiemetic Ondansetron 
Antitumor agents Paclitaxel, Doxorubicin, Daunorubicin, Vinblastine, Vincristine, 
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 Actinomycin D, Docetaxel, Etoposide, Imatinib 
β-Adrenoceptor antagonists Bunitrolol, Carvedilol, Celiprolol, Talinolol, Reserpine 
Ca
++
 Channel Blockers Diltiazem, Mibefradil 
Cardiac drugs/Antiarrhytmics Digitoxin, Digoxin 
H1 histamine receptor antagonists Fexofenadine, Terfenadine 
HIV-protease Inhibitors Ampenavir, Indinavir, Nelfinavir, Saquinavir, Ritonavir 
Immunosupressants Cyclosporine A, Sirolimus, Tacrolimus 
Opioids Loperamide, Domperidone, Morphine, Pentazocine, Methadone, 
Asimadoline, Fentanyl 
Steroids 
 
Dexametasone, Methylprednisolone, Aldosterone, Progesterone, 
Hydrocortisone, Cortisol, Corticosterone 
Others Colchicine, Itraconazole, Phenothiazines, Ivermectin 
Inhibitors 
Antiarrhythmics Amiodarone, Quinidine, Verapamil, Felodipine, Nifidipine, 
Dilitiazem 
Anticancer drugs Actinomycin D, Doxorubicin, Vinblastine 
Antibiotics Clarithromycin, Erythromycin. 
Antidepressants Paroxetine, Sertraline, Desmethylsertraline 
Proton pump inhibitors  Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole 
Others Valspodar (PSC), Cyclosporine A, Ketoconazole 
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II EXPERIMENTAL WORK 
 
 
6 BACKGROUND 
 
Over the past two-three decades the involvement of transporters in drug distribution, 
metabolism and excretion has come to our knowledge. In vitro studies are used to 
screen transporter substrates and inhibitors to predict drug-drug interactions. Replacing 
in vivo studies with in vitro studies saves money and time and is more ethical.  However 
there are still many uncertain aspects that need to be considered and more clear 
guidelines are needed for in vitro transporter studies (Giacomini et al. 2010). In this 
experimental part four P-gp substrates are analyzed with two in vitro methods and the 
results are reviewed in light of previous in vitro and in vivo studies.  
 
6.1 In vitro study methods 
 
Both FDA and EMA recommend using Caco-2 cells for investigating transporter 
substrates (EMA 2012, FDA 2012). An alternative tool for research is a cell line that 
overexpresses a human transporter protein such as MDCKII (FDA 2012). MDCKII 
(Madin Darby Canine Kidney) -cell line is originally renal epithelia from dog (Tang et 
al. 2002). The cell line has been transfected with human P-glycoprotein (P-gp) coding 
gene ABCB1 to produce MDCKII-MDR1-cell line. Tang et al. (2002) demonstrated 
that MDCKII-MDR1 cell line expresses higher levels of P-gp than MCDKII wild type 
(MDCKII-wt) or caco-2 cells. MDCKII cells form uniform cell monolayer and tight 
junctions substantially faster than caco-2 cells (3 days compared to 30 days) (Irvine et 
al. 1999).  
 
Another option (though not approved by authorities) is to use membrane vesicles which 
are made from cell membrane and inverted into inside-out conformation (Giacomini et 
al. 2010). The cytoplasmic membrane and thus also the binding site for efflux 
transporters is facing outside the vesicle (Glavinas et al. 2008). The inside-out vesicles 
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were first prepared and characterized from red blood cell plasma ghost membranes 
(Steck et al. 1970). Vesicular transport assay has been utilized already in 1988 for 
studying P-gp mediated transport (Horio et al. 1988). The vesicles were prepared from 
multidrug resistant human carcinoma cells containing p-glycoprotein and the group was 
able to demonstrate ATP-dependent transport of vinblastine.  Membrane vesicles 
prepared from Sf9 (Spodoptera frugiperda ovarian) cells expressing P-gp were first 
used to demonstrate that a drug can stimulate ATPase-activity (Sarkadi et al. 1992). 
Liberation of inorganic phosphate (Pi) was higher when a drug and Mg-ATP was 
incubated with vesicles infected with MDR1-baculovirus than uninfected vesicles. The 
advantage in using the Sf9 membrane vesicles is the lack of human transporter 
expression because the cells are insect-origin. Common limitation in vesicular assay is 
the lack of high permeability drugs showing difference between passive and ATP-
dependent transport (Glavinas et al. 2008).  
 
6.2 Properties of the selected test drugs 
 
A renin-enzyme inhibitor aliskiren (Rasilez
®
, Tekturna
®
) is used for treatment of 
essential hypertension alone or with other blood pressure lowering agents (drug@FDA, 
www.ema.europa.eu). An adrenergic β1-receptor antagonist and partial β2 receptor 
agonist celiprolol (Selectol
®
, Celectol
®
, Cardem
®
) and a selective β1 receptor talinolol 
(Cordanum
®
) are used for treatment of high blood pressure and coronary decease 
(Duodecim 2013, Martindale 2007). A selective H1-receptor antagonist fexofenadine 
(brand names Telfast
®
 and Allegra
®
) is used to treat seasonal allergic rhinitis and 
chronic idiopathic urticarial. (drug@FDA). A P-gp inhibitor itraconazole (brand name 
Sporanox
®
) is a synthetic triazole antifungal drug which is used for treatment of lung 
and general fungal infections and nail fungal infections (drugs@FDA).  
 
The fact that mentioned drugs are used to treat long-term conditions means that they are 
probably used simultaneously with other medical agents. This increases the risk for 
drug-drug interaction which can potentially cause loss of effect or undesirable side 
effects by altering the ADME (absorption, distribution, metabolism and elimination) 
properties of the drug(s). Aliskiren, fexofenadine, talinolol and celiprolol show P-gp 
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dependent kinetics in vivo. The first three drugs are classified as P-gp substrates in FDA 
drug interaction studies-guidance for industry (FDA 2012). P-gp mediated interactions 
of these drugs have been demonstrated to be clinically significant (Table 4).  
 
Table 4. In vivo interactions of the test drugs and classification of interaction according 
to SFINX-PHARAO (Class C3 indicates clinically significant interaction which can 
tolerated with dose adjustment, D3 indicates clinically significant interaction which 
should be avoided). Arrow up means increasing and arrow down decreasing parameter 
when P-gp substrate is administered with inhibitor/inducer compared to the situation 
when drug is administered alone. 
 
Substrate 
 
Inhibitor/inducer 
In vivo difference  
SFINX-significance  
class
10 AUC Cmax 
Fexofenadine Itraconazole
1
 ↑ 2-3,3x ↑ 1.8-2.3x C3 ( P-gp) 
 
Carbamazepine
2
 ↓ 0.4-0.6x ↓ 0.7 x C3 ( P-gp) 
 
Verapamil
3
 ↑ 1.7-2.1x ↑ 1.5-2.2x C3 (P-gp) 
Celiprolol Itraconazole
4
 ↑ 1,8x ↑ 1,3x C3 (P-gp/CYP3A4) 
 
Rifampicin
5
 ↓ 0.4x ↓ 0.7x C3 (P-gp) 
Talinolol Rifampicin
6
 ↓ 0.6 ↓ 0.6x - 
 
Carbamazepine
7
 ↓ 0.85x - - 
Aliskiren Itraconazole
8
 ↑ 6x - D3 (P-gp) 
 Verapamil
9
 ↑ 2x ↑ 2x C3 (P-gp) 
*SFINX (Swedish, Finnish, Interaction X-referencing) drug interaction database
 
1
 Shimizu et al. 2006a, Shimizu et al. 2006b, Tateishi et al.2008 
2 
Akamine et al. 2012, Yamada et al. 2009 
3
 Lemma et al. 2006, Sakugawa et al. 2009 
4
 Lilja et al. 2003 
5
 Lilja et al. 2004a 
6
 Westphal et al. 2000 
7
 Giessmann et al. 2004 
8
 Tapaninen et al. 2011 
9
 Rebollo et al. 2011 
10
 Duodecim 2013 
 
 
Pharmacokinetic properties of the test drugs are presented in (Table 5).  All four drugs 
have low bioavailability which could refer to low solubility or permeability, gut wall 
metabolism or efflux transport, possible mediated by P-gp. The drugs are excreted 
mainly with feces or via urine (Lilja et al. 2004a, Kagan et al. 2007, Waldmeir et al. 
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2007, Lappin et al. 2010). Only 1-5 % of the absorbed drug dose is metabolized in the 
body which makes the drugs interesting P-gp probe drugs because expression of 
metabolizing enzymes doesn’t affect their pharmacokinetics (Lilja et al. 2004a, Kagan 
et al. 2007, Martindale 2007, Waldmeir et al. 2007). The dose dependency rather than 
time dependency of talinolol pharmacokinetics also suggests that there is some active, 
saturable mechanism involved (Kagan et al. 2010). In addition celiprolol and 
fexofenadine have shown saturable pharmacokinetics and dose dependent 
bioavailability (Karlsson et al. 1993, Lappin et al 2010).  
 
Table 5. Pharmacokinetic properties of test drugs 
Parameter Unit Aliskiren 
1 
Celiprolol 
3 
Fexofenadine 
5 
Talinolol 
7 
Dose  mg 150
 
100 
 
60 
 
50 
 
Tmax  h 1 (0-5)
 
4 (3-6)  2 (0.5–4)  3.3 ± 1.5  
Cmax  ng/ml 142 ± 42 
 
277 ± 229 
 
332±252 
 
45 ± 24 
 
AUC0-∞  ng h/ml 625 ± 293 1266 ± 791 
 
1801 ± 979 
 
427 ± 192 
 
T ½ (p.o.) 
 
h 34.0 ± 9.7
 
4.8 ± 1.3 
 
6.6 ±3.1 
 
9.1 ± 4.1 
 
BA**  % 2,5 
2
 30-70 
4 
30 
6 
55 
8 
CL renal
 
ml/min 24.67 ± 4
 
205 ± 45.5  55.6 ± 21.8 
 
220 ± 102 
 
Ae * mg 0.567 ± 0.289
 
13.9 ± 6.5 
 
5.6 ± 3.3 
 
4.5 ±1.9 
 
*Ae = Amount excreted to urine 
**Bioavailability 
1
 Tapaninen et al. 2011. Ae 12 hours.  
2
 drugs@FDA 
3
Lilja et al. 2003  
4
 Lilja et al. 2004a 
5
 Tateishi et al. 2008 Ae 0-24 hours 
6
 Lappin et al. 2010. Fexofenadine dose 120 mg 
7
 Schwartz et al. 2007 Urinary excretion of unchanged talinolol from 0 to 48 h. CLr from 0 to 24 h.  
8
 Kagan et al. 200. Dose 100 mg 
 
The molecular formulas and physicochemical properties of the drugs are presented in 
Table 7. and Table 8. The aqueous and lipid solubility of the drugs is variable. 
According to FDA a drug substance is highly soluble if the ratio of highest oral dose 
(mg) to the solubility (mg/ml) is less than 250 ml over the pH range 1-7.5 (at 37 ˚C).  
Aliskiren, celiprolol and talinolol meet these criteria at pH 7.4 but fexofenadine is not 
highly soluble according to this definition (Table 6). The LogD7.4 values for the test 
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drugs vary from -0.22 to 2.30. Fexofenadine which is the most hydrophilic compound in 
this group is classified as a low permeable drug and has rather low permeability through 
Caco-2 cells (Chen 2007).  
  
Table 6. Solubility of the maximal oral daily dose of the test drugs in 250 ml (at pH 7.4 
and 37 ˚C) 
 Aliskiren Celiprolol Fexofenadine Talinolol 
Maximal oral daily dose (mg) 300 
1
 600 
1
 180 
1
 300 
2
 
Solubility in 250 ml (mg) >300 1830 2.5 563 
1
 Micromedex 2.0 
2
 Martindale 2007 
 
Table 7. Molecular formulas for investigatory-drugs 
Fexofenadine 
(as hydrochloride salt)
1 
Celiprolol 
(as hydrochloride salt)
2 
 
 
 
Talinolol3 
Aliskiren 
(as hemifurete salt)
1 
 
 
1 drugs@FDA 
2 European Pharmacopea 7th edition 
3Martindale 2007 
3European Bioinformatics Institute 2013 
 
Table 8. Physicochemical properties of the P-gp substrates 
Parameter Aliskiren 
 
Celiprolol 
 
Fexofenadine  Talinolol 
 
Molecular mass 
(g/mol) 
551.8
3 
379.49
1 
501.66 
2 
363,49
1 
33 
 
Aqueous solubility  
(pH 7.4) (mg/ml) 
>350
3 
7.32
1 
0.81
6 
2.26
1 
Papp  
(cm/s x10
-6
) 
- - 0.17 ± 0.08
4
 1.08 ±0.29
5
 
logP
1 
2.74
 
1.92
 
4.8
 
3.2
 
logD 7.4
1 
0.07
 
-0.22
 
2.30
 
1.03
 
logD 5.5
1 
-0.35 
 
-1.14 
 
2.28 0.14 
pKa
1 9.49 (base)
 
 
9.11 (base)
 
 
9.56 (acid)
 
4.43 (base)
 
0.89 (base) 
 
PSA
1 
146.1 
 
90.9
 
81
 
82.62
 
1 Calculated by ACD labs 8.08 (Canada)  
2  European pharmacopeia 7th edition 
3 drugs@FDA 
4 Petri et al. 2004 Determined in caco-2 cells (A-B) with 50 µM concentration 
5 Deferme et al. 2002 Determined in caco-2 cells (A-B) with 100 µM concentration 
6 Chen 2007 
 
 
7 AIMS OF THE STUDY 
 
The purpose of this experimental work was to study P-gp-mediated transport of 
aliskiren, celiprolol, fexofenadine and talinolol in MDCKII-MDR1-cells and in 
membrane vesicles extracted from P-gp expressing Sf9 cells.  The aims of the study 
were 
(1) to assess the feasibility of using the vesicle assay in P-gp interaction studies with 
hydro- and lipophilic drugs,  
(2) to determine Km and Vmax‒values for aliskiren with vesicles and cells in order to 
compare the methods,  
(4) to determine efflux ratios for the substrates with and without inhibitors in order to 
find out if they are in vitro P-gp substrates and  
(5) to compare in vitro results to in vivo results in order to see if they can be used to 
predict in vivo effect. 
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8 MATERIALS AND METHODS 
 
8.1 Drug compounds 
 
Celiprolol hydrochloride, fexofenadine, talinolol and itraconazole were obtained from 
Santa Cruz Biotechnology (Germany). Aliskiren hydrochloride was obtained from 
Santa Cruz Biotechnology (Germany) for vesicular transport assay and from Toronto 
Research Chemicals Inc. (Germany) for the cell permeability test. 
 
For the vecicular transport assay stock solutions of 10 mM were prepared in dimethyl 
sulfoxide (DMSO). The final concentration of DMSO in test solution was 1 %. For the 
cell permeability experiments fexofenadine and talinolol stock solution of 10 mM and 
aliskiren hydrochloride stock solution of 5mM were prepared in DMSO. Celiprolol 
hydrochloride stock solution was prepared in Milliq water. Test solutions were prepared 
in transport buffer. The final concentration of DMSO in the test solution was 0.1-0.2 % 
except for the test for Km-determination of aliskiren where the DMSO concentration 
was 0.6 %. Itraconazole 10 mM stock solution was prepared in DMSO and further 
diluted to 10 µM test solution in transport buffer. 
 
8.2 Control compounds 
 
Control molecules Lucifer yellow and paracetamol (one experiment) were used in cell 
assay. Cyclosporine was used to study passive permeation of P-gp substrates. 
Paracetamol was obtained from Santa Cruz Biotechnology (Germany) and cyclosporine 
and Lucifer yellow were obtained from Sigma-Aldrich (Germany).  
 
Lucifer yellow is frequently used as a paracellular marker. It is highly fluorescent and 
therefore can be measured optically. It was used to control the integrity and uniform 
quality of the cell monolayer. Lucifer yellow 20 mM stock solution was prepared in 
transport buffer and further diluted to 250 μM test solution. One part of the 
experimental work was to test the effect of polar organic solvent DMSO on cell 
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integrity. 0.1-1 % (v/v) of DMSO was added to the 250 µM Lucifer yellow test solution 
to produce DMSO concentration of 0.1-5 % (v/v). 
 
An analgetic and antipyretic agent paracetamol (acetaminophen) was used as a model 
compound for a high or low permeability boundary drug. Paracetamol stock solution of 
10 mM and test solution of 50 µM were prepared in transporter buffer. Cyclosporine is 
an inhibitor of several transporters (P-gp, OATPs, BCRP) and therefore it can used to 
prevent active transport and study the passive permeability (FDA 2012). Cyclosporine 
concentration was used in the cell assay to find out the passive permeability of the test 
drugs. Cyclosporine 10 mM stock solutions were prepared in DMSO and further diluted 
to 10 µM test solution in transport buffer.  
 
8.3 Vesicular transport assay 
 
The membrane vesicles were prepared from P-gp-gene containing recombinant 
baculovirus -infected Sf9 (Spodoptera frugiperda) insect cells. The total protein 
concentration of stock solution was 5 mg/ml. The membranes were supplemented with 
cholesterol to improve function of P-gp and gain cholesterol concentration closer to 
mammal cells. The cholesterol concentration was about 80 µg/ mg per total protein 
concentration as measured with the Amplex Red Cholesterol Assay kit (Invitrogen, 
USA). 
 
8.3.1 The test protocol 
 
The membrane vesicle solution with protein concentration of 5 mg/ml and cholesterol 
concentration of 5 mM was diluted 1:5 in freshly prepared assay mix (5 ml 0.1 M 
MOPS-Tris, 5 ml 0.14 M KCl and 0.75 ml 0.1 M MgCl2). 50 µl of the membrane 
vesicle solution per well was distributed to 96-well plate. The P-gp substrate was added 
either directly to the membrane solution before pipetting into to the wells, or in 0.75 µl 
to the wells. The plate, freshly prepared 12 mM Mg-adenosine triphosphate solution 
(Mg-ATP) in assay mix and plain assay mix were incubated at 37 C˚ for 10 minutes. 
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The reaction was initiated by adding 25 µl of Mg-ATP-solution or assay mix to desired 
wells.  
 
The plate was incubated in 37 C˚ for predetermined time and the reaction was stopped 
by adding 200 µl of ice cold washing mix (200 ml 0.1 M MOPS-Tris, 35 ml 1 M KCl 
and 265 ml MilliQ water) to the wells. The samples were transferred to the 96-well 
filter plate and the solution was removed by suction. The wells were washed five times 
with ice cold washing mix and after that the plate was allowed to dry in room 
temperature for 60 minutes. The vesicles were broken by incubating the wells with 100 
µl of 0.1 M ammonium hydroxide solution and the samples were transferred to 96-well 
plate by suction. 
 
Transported drug amount inside the vesicles was determined with and without ATP in 
triplicates. ATP dependent transport (molecules/time/mg of protein) was calculated by 
reducing transport rate in well incubated without ATP from transport rate in wells 
incubated with ATP. 
 
8.3.2 Test circumstances and concentrations 
 
At first the vesicular transport assay was performed for all the test drugs with 
concentrations of 1, 10 and 100 μM and incubation time 30 min in order to determine 
the best concentration for incubation time optimizing. The concentration that gave the 
biggest ratio between active and passive transport was chosen for further analysis. The 
incubation time was optimized by incubating test plates for 1, 3, 10 or 30 min. 
Celiprolol concentrations of 1, 2, 5, 10, 20, 50, 75 and 100 μM and aliskiren 
concentrations of 0.5, 1, 2, 4, 8, 10, 15 and 30 μM were used for the determination of 
Km-values.  
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8.4 Cell permeability assay 
 
8.4.1 Cell culture of MDCKII-MDR1-cells 
 
The Madin-Darby canine kidney II (MDCKII) cells expressing human multidrug 
resistance protein I (MDR1) (P-glycoprotein) were originally obtained from Netherland 
Cancer Institute (Amsterdam). The cells were grown in cell culture flasks and split 
twice a week. The growth medium was prepared from D-MEM (Dulbecco’s Modified 
Eagle’s medium) (31885, Gibco USA) which was supplemented with 10 % FBS (foetal 
bovine serum) and Penicillin-Streptomycin solution (1 %, Gibco). Before splitting the 
cells were washed with DPBS (Dulbecco’s phosphate buffered saline) (-Ca and -Mg, 
14200 Gibco). The cells were detached from the bottom of the flask by incubating them 
with TrypLe Express (12604 Gibco) for 8-10 min and divided in 1:9. 
 
The cells were grown on 12-well plate with polyester membrane inserts (3460, Costar 
Transwell USA) with diameter of 0.4µm and area 1.12 cm
2
 (Figure 14). The cell density 
was measured with the help of Bürker chamber and microscope and seeding density was 
adjusted to 0.8 x 10
6
 cells /ml. Before permeability experiments the cells were grown at 
37 C˚ and 5 % CO2 for 5 days.  Media was changed every day in both apical and 
basolateral side. The passage number of the cells used in the experiments with talinolol, 
celiprolol, aliskiren, fexofenadine and paracetamol varied between 13 and 17 and with 
Lucifer yellow between 12 and 18. 
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Figure 14. Design of the Transwell permeable supports. The upper and the lower 
compartment represents the apical and the basolateral compartments, respectively. The 
cells grow on the microporous membrane (Corning Life Sciencis 2013).  
 
8.4.2 Determination of trans-epithelial electrical resistance 
 
The integrity of the cell monolayer was evaluated by measuring trans-epithelial 
electrical resistance (TEER, Ωcm2). Values were determined with EVOM (Epithelial 
Voltohmmeter) with STX2 electrode (World Precision Instruments, USA). TEER 
values were measured at 37 C˚ in growth media at 4 and 5 days after the seeding and in 
buffer before and after the experiment. Before measuring TEER-values in buffer the 
monolayers were washed 2 times with pre-warmed transport buffer solution. The 
TEER-values of the epithelial monolayer were calculated with Equation 1.  
 
Equation 1      
     (     )        (                )       (                   ) 
 
8.4.3 Determination of permeability of the P-gp substrates 
 
Celiprolol, fexofenadine and talinolol concentrations of 10 µM and aliskiren 
concentration of 2 µM were used for determination of permeability. The permeability 
tests for P-gp substrates were performed from the apical to the basolateral side (A-B) 
and from the basolateral to the apical side (B-A).  In addition, permeability of 
fexofenadine (10 µM), celiprolol (10 µM) and aliskiren (2 µM) was determined with 10 
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µM itraconazole for both directions. Permeability of aliskiren (2 µM) and talinolol (10 
µM) with cyclosporine was determined from A to B and for celiprolol (10 µM) in both 
directions. The Km-determination of aliskiren was performed from the apical to the 
basolateral side and aliskiren concentrations of 0.5, 1, 2, 4, 6, 12, 30, 100 µM and was 
used for determination of Km and Vmax values.  
 
Experiments were performed in transport buffer: HBSS (Hank’s balanced salt solution 
14025, Gibco) supplemented with 10 mM HEPES (15630 Gibco) (pH 7.4). The liquid 
volume was 1500 µl and 500 µl at the basolateral and the apical side, respectively. 
Before experiments the cell monolayers were washed twice with the transport buffer 
and incubated for 30 min at 37 C˚. Test was performed in 12-well plates (3512, Corning 
costar USA) which were pre-incubated for 10 min at 37 C˚ with test solution (B-A test) 
or buffer solution (A-B). At the beginning of the experiment the inserts containing the 
cell monolayer were emptied of buffer and transferred to the test plate. The test solution 
or the transport buffer was added to the apical side with 60 s interval. Experiments were 
performed at 37 C˚ and shaking 200 rpm. Samples of 200 µl were taken from receiver 
side at four time points and were replaced with warm transport buffer. Samples of test 
solutions were taken at the beginning and at the end of the experiment. 
 
Apparent permeability (Papp, cm/s) was calculated with Equation 2 where dM/dt 
(µmol/s) is the slope of the drug concentration in the receiver chamber with time, C0 
(µM) is the concentration in the donor chamber when t=0 and A (cm
2
) is the filter 
surface area. 
 
Equation 2 
      
  
  
  
 
(    )
 
 
The efflux ratio (ER) was calculated for test drugs with and without inhibitors with 
Equation 3 where Papp (A to B) is the apparent permeability of the substrate into the 
basolateral (absorptive) direction and Papp (B to A) is the apparent permeability of the 
substrate to the apical (secretive) direction. 
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Equation 3  
    
    (      )
     (      )
 
 
8.5 Analytics 
 
The samples were frozen at -20 ˚C and stored for the analysis (variable time). Lucifer 
yellow was measured within an hour by Fluorometry Varioscan (Thermo Electron 
corporation, Massachusetts, USA) in a black 96-well plate with clear bottom (3631, 
Corning costar, USA). The excitation and emission wavelengths of 425 and 538 nm 
were used, respectively.  
 
The other compounds were analyzed with combined ultra-performance liquid 
chromatorgraphy and mass spectrometry (UPLC-MS). The liquid chromatography 
separation of samples was performed with Waters Acquity UPLC (Waters, 
Massachusetts, USA) (HSS T3 column, column dimensions 2.1  x 100 mm and particle 
size 1.8 µm, flow rate 0.3 ml/min, injection volume 0.5 µl, T 25 °C, mobile phases H2O 
+ 0.1 % Formic Acid (gradient 90-10-90 %) and acetonitrile + 0.1 % Formic Acid 
(gradient 10-95-10 %)). The mass spectrometric measurements were performed with 
Waters TQ-S triple quadrupole mass spectrometer (Waters, Massachusetts, USA) 
(electrospray ionization: ESI+, capillary voltage 3.7 kV, desolvation temperature 500 °C 
and gas flow 800 l/h, cone gas flow 150 l/h, desolvation, collision and cone gas 
nitrogen, scan mode MRM, dwell time 0.034-0.068 s and retention time 1.8-2.2 min). 
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9 RESULTS 
 
9.1 Vesicular transport assay 
 
9.1.1 ATP dependent transport with different test concentrations 
 
The ATP dependent transport of talinolol, fexofenadine and celiprolol with test 
concentrations 1, 10 and 100 µM is presented in Table 9. The concentration 
optimization for aliskiren was not performed because this was done earlier for the used 
vesicles by Koskenkorva (2012). Talinolol and celiprolol failed to show ATP dependent 
transport with concentration 10 and 100 µM and fexofenadine failed show active 
transport with concentration 100 µM. The ATP-dependent transport was highest with 
concentration 1µM for fexofenadine. Also highest ratio between +ATP/-ATP-transport 
was measured for fexofenadine and lowest for celiprolol. 
 
Table 9. ATP-dependent transport of talinolol, fexofenadine and celiprolol with 
concentrations 1, 10, and 100 µM (n=3) in MDR1-Sf9 membrane vesicle assay. 
Incubation time was 30 min. (Average ± SD)  
Concentration (µM) 1 10 100 
Talinolol 
ATP-dependent transport 
(pmol/min/mg protein) 
   0.168 ± 0.1   
 
- - 
Ratio (+ATP/-ATP) 2.1 ± 1.2 0.73 ± 0.49 0.66 ± 0.43 
Fexofenadine 
ATP-dependent transport 
(pmol/min/mg protein) 
0.348 ± 0.34 0.215 ± 0.78 - 
Ratio (+ATP/-ATP) 2.6 ± 1.7 1.3 ± 1.2 0.55 ± 0.82 
Celiprolol 
ATP-dependent transport 
(pmol/min/mg protein) 
0.044 ± 0.052 - -  
Ratio (+ATP/-ATP) 1.6 ± 0.99 0.46 ± 0.79 -  
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9.1.2 ATP dependent transport with different incubation times 
 
The ATP dependent transport of talinolol, fexofenadine and aliskiren (1 µM) with test 
incubation times 1, 3, 10 and 30 min is presented in Table 10. The incubation time 
optimization failed with celiprolol and further studies were performed with incubation 
time 1 min. The transport rate decreased when the incubation time increased with all 
three compounds. Talinolol failed to show active transport with incubation time 30 min. 
 
Table 10. ATP-dependent transport of talinolol, fexofenadine and aliskiren with 
incubation times 1, 3, 10, and 30 min (n=3) in sf9 membrane vesicle assay. 1µM 
concentration was used (Average ± SD) 
Incubation time (min) 1 3 10 30 
Talinolol 
ATP-dependent transport 
(pmol/min/mg protein) 
4.7 ± 7.3   
 
0.56 ± 0.3 0.22 ± 0.0 - 
Ratio (+ATP/-ATP) 2.5 ± 2.3 1.2 ± 0.28 1.1 ± 0.11 1.0 ± 0.33 
Fexofenadine 
ATP-dependent transport 
(pmol/min/mg protein) 
2.4 ± 1.4   
 
0.37 ± 0.24 0.11 ± 0.13 0.04 ± 0.02 
Ratio (+ATP/-ATP) 2.2 ± 0.79 1.4 ± 0.32 1.3 ± 0.42 1.4 ± 0.27 
Aliskiren 
ATP-dependent transport 
(pmol/min/mg protein) 
   14 ± 6.7   
 
5.4 ± 2.2 1.6 ± 0.8 0.76 ± 0.31 
Ratio (+ATP/-ATP) 1.6 ± 0.37 1.9 ± 0.4 2.1 ± 0.7 2.9 ± 1.2 
 
 
9.1.3 Km determination 
 
The results from Km determination of celiprolol are presented in Figure 15. ATP 
dependent transport of celiprolol did not saturate with concentrations 1-100 µM and 
transport rate increased with increasing concentration. The maximal transport rate of 
celiprolol with concentration of 100 µM was 170 ± 144 pmol/mg/min.  
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Figure 15. ATP dependent transport of celiprolol with concentrations of 1-75 µM and 
incubation time 1 min (Average ± SD) 
 
The transport of aliskiren was determined with concentrations of 0.5-30 µM but 
aliskiren failed to show ATP-dependent transport when concentration increased over 2 
µM. With aliskiren concentration of 4 µM passive transport was 1.3-fold compared to 
ATP- dependent transport. The transport rate decreased when concentration of aliskiren 
increased (Figure 16). 
 
 
Figure 16. ATP dependent transport of aliskiren (nmol/mg/min) decreased when 
concentration of aliskiren increased. Incubation time was 1 minute (Average ±SD) 
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9.2 Cell assay 
 
9.2.1 Permeability of control compounds and TEER 
 
Results from paracetamol cell transport experiment for each well are presented in 
Appendix 3. The average apparent permeability of paracetamol from apical to the 
basolateral side and the average mass balance of the paracetamol wells are presented in 
Table 11.  
 
Table 11. Transport of paracetamol 50 µM (average ± SD, n=2, passage 13) from the 
apical to the basolateral side (A-B) and mass balance. The samples were collected at 30, 
60, 90 and 120 min after initiation of the experiment. 
Substrate, 
concentration 
Papp x10
-6
 (cm/s) Mass balance % ± SD 
A-B A-B 
Paracetamol, 
50 µM 
17.2 ± 0.1 103 ± 0.14 
 
 
Permeability test of Lucifer yellow was performed only from the apical to the 
basolateral side and concentration was determined in four time points (30-120 minutes). 
Transport of Lucifer yellow in single wells is presented in Appendix 5.  The average 
permeability of Lucifer yellow was from 0.047 ± 0.025 to 1.2 ± 1.1 x10
-6
 cm/s when the 
cell passage number varied from 12 to 18 (Table 12). The difference between the 
highest and lowest permeability value was about 25-fold. The permeability increased 
with increasing passage number. The apparent permeability values in the experiment 
with tests compounds varied from 0.047 ± 0.025 to 1.0 ± 0.28 x10
-6
 cm/s. 
 
Table 12. Papp values of Lucifer yellow (250µM) in MDCKII-MDR1-cells with different 
passage numbers. Test was performed from the apical to the basolateral side 
Passage 
number 
Papp x10
-6
 
(cm/s) 
12 0.077 
13 0.72, 0.057 
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14 0.047 
15 0.48 
16 0.13 
17 1.0 
18 1.2 
 
The permeability of Lucifer yellow increased when concentration of DMSO increased 
(Figure 17). When DMSO concentration was 5 % the permeability of Lucifer yellow 
increased 2.7-fold compared to well where DMSO concentration was 0 %. Additionally 
DMSO concentration of 0.1 % and 0.2 % increased Lucifer permeability 2.1- and 2.3 
fold, respectively. 
 
 
 
Figure 17. Effect of DMSO (dimethyl sulfoxide) concentration (0-5 %) on apparent 
permeability (Papp) of Lucifer yellow (250 µM) (n=1-2, passages 13 and 16). 
 
The average (±SD) TEER value during P-gp substrate experiments in the buffer before 
the experiment was 62 ± 12 Ωcm2 and after the experiments 61 ± 8 Ωcm2. The TEER 
values did not have great variation between experiment and no significant drop of the 
values was detected after the experiment. TEER values during each experiment are 
presented in Appendix 6. TEER values were measured in growth media on day 4 and 5 
after the seeding but no significant increase was detected on day 5 compared to day 4. 
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The average TEER values in the media on 4
th
 day and 5
th
 day were 77 ± 6 Ωcm2 and 70 
± 9 Ωcm2, respectively. 
 
9.2.2 Permeability of substrates 
 
The average apparent permeability values of P-gp substrates alone are presented in 
Table 13. Results from single wells are presented in Appendix 1. Celiprolol 
demonstrated the highest apparent permeability (Papp) while aliskiren demonstrated the 
lowest apparent permeability. Aliskiren failed to show results with concentration 2 µM 
and Km determination due low recovery to the other side of the membrane. However 
permeability was obtained with 30 µM from the apical to the basolateral side. Talinolol 
showed the highest efflux ratio and celiprolol the lowest. 
 
Table 13. Apparent permeability (Papp) of the test compounds through MDCKII-MDR1 
cell monolayer from the apical to the basolateral (A-B) side and from the basolateral to 
the apical side (B-A), recovery of test molecules after experiment (average % ± SD) and 
efflux ratios. The samples were collected at 30, 60 and 90 min (fexofenadine, n= 3, 
passage 13), at 30, 60, 90 and 120 min (talinolol, celiprolol, n=3, passages 14 and 13, 
respectively) or at 60, 90 and 120 min (aliskiren, n=2, passage 17) after initiation of the 
experiment. 
Substrate 
Papp x10
-6 
cm/s ± SD
 
Efflux 
ratio 
Recovery % ± SD 
A-B B-A A-B B-A 
Fexofenadine 
10 µM 
0.19 ± 0.12 0.57 ± 0.13 3.0 94 ± 11 88 ± 66 
Talinolol 
10 µM 
0.25 ± 0.08 3.6 ± 0.79 14 94 ± 9 101 ± 15 
Celiprolol 
10 µM 
0.50 ± 0.30 0.85 ± 0.31 1.7 79 ± 3 70 ± 1 
Aliskiren 
30 µM 
0.056 ± 0.002 - - 191 ± 3 - 
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9.2.3 Permeability of substrates with inhibitors 
 
The average apparent permeability values of the P-gp substrates with P-gp inhibitors 
itraconazole and cyclosporine are presented in Table 14. Results for single wells are 
presented in Appendix 2. Permeability of aliskiren (2 µM) with itraconazole was not 
obtained because of the low recovery of aliskiren on the receiver side of the membrane. 
Itraconazole had no effect on celiprolol or fexofenadine efflux ratio. Permeability of 
celiprolol to the absorptive direction is the same with and without itraconazole but 
permeability of fexofenadine is slightly changed with itraconazole. Celiprolol transport 
in the absorptive direction was clearly increased when administered with cyclosporine 
compared to the administration alone or with itraconazole. The A-B transport of 
celiprolol with cyclosporine was even higher than B-A transport of celiprolol alone. 
Also A-B permeability of talinolol was increased when administered with cyclosporine 
however remained clearly lower than B-A permeability of talinolol alone. 
 
Table 14. Apparent permeability (Papp) of test components with inhibitors through 
MDCKII-MDR1 cell monolayer from the apical to the basolateral side (A-B) and from 
the basolateral to the apical side (B-A), recovery of test molecules after experiment 
(average % ± SD) and efflux ratios (ER). The samples were collected at 30, 60 and 90 
min (fexofenadine and celiprolol, n= 2-3, passage 13) or at 30, 60, 90 and 120 min 
(talinolol, n=3, passage 14) 
Substrate Inhibitor 
Papp x10
-6
cm/s ± SD
 
ER 
Recovery 
% ± SD 
A-B B-A A-B B-A 
Fexofenadine 
10 µM 
Itraconazole 
10 µM 
0.26 ± 0.16 0.75 ± 0.44 2.9 93 ± 4 
117 ± 
13 
 
Celiprolol 
10 µM 
 
Itraconazole 
10 µM 
0.53 ± 0.20 0.96 ± 0.29 1.8 93 ± 5 79 ± 5 
Celiprolol 
10 µM 
Cyclosporine 
10 µM 
1.65 ± 1.74 0.46 ± 0.64 0.3 79 ± 3 67 ±3 
Talinolol 
10 µM 
Cyclosporine 
10 µM 
0.76 ± 0.63 - - 86 ± 13 - 
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10 DISCUSSION 
 
10.1 Feasibility of vesicle transport assay 
 
Celiprolol and aliskiren are more hydrophilic molecules than talinolol and fexofenadine 
which gives reason to assume they would be better subjects for vesicular transport 
assay. Hydrophobic molecules tend to absorb to membranes and therefore make it more 
difficult to predict the transport in membrane vesicles (Giacomini et al. 2010). Another 
problem is high to medium permeability subjects escaping from inside the vesicles 
(Glavinas et al. 2008). In agreement with this hydrophilic aliskiren demonstrated higher 
ATP dependent transport rates than fexofenadine and talinolol (1 µM, 1 min). In 
addition talinolol failed to show active transport with higher concentrations (10 and 100 
µM) and therefore appeared to be poor subject for the vesicle transport assay. 
Fexofenadine showed the highest ratio between ATP dependent and passive transport 
and the highest transport rate with incubation time of 1 min which could mean that it 
escapes from vesicles when incubated for longer period. On the other hand celiprolol 
showed low efflux transport rate even though it is the most hydrophilic drug. This 
however is probably because of the low P-gp affinity but it also could also support the 
theory that P-gp substrates are hydrophobic and molecules enter to the P-gp binding site 
through hydrophobic gate.  
 
Celiprolol showed non‒ saturable kinetics up to 100 µM from which can be concluded 
that Km-value of celiprolol is over 100 µM. This finding is rational because Lipka et al. 
(1998) determined 10-fold higher Km-value of 1±0.23 mM for celiprolol in caco-2 cells. 
Aliskiren failed to show ATP dependent transport with concentrations over 3 µM. This 
is in disagreement with another master’s thesis work where Km-value of aliskiren was 
successfully determined (Koskenkorva 2012). The highest transport rate accomplished 
for aliskiren was 14 pmol/mg/min (2 µM) which is significantly lower than Vmax value 
of 890 pmol/mg/min determined in the previous work. 
 
In this thesis cholesterol was added to the Sf9 membrane vesicles containing cholesterol 
in order to enhance function of P-gp which could have affected to the results. The 
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cholesterol content of Sf9-cells is lower than in mammal cells and cell cholesterol 
content cholesterol have been suspected to have an effect on activity of ABC 
transporters (BCRP, P-gp) (Kalsson et al. 2010, Pál et al. 2007). There is also evidence 
that cholesterol can affect the ATPase activity of P-gp (Eckford and Sharom 2008, 
Garrigues et al. 2002). Garrigues et al. (2002) demonstrated slightly higher P-gp 
ATPase activity in the presence of 20 % cholesterol compared to 0 and 30 % in DMPC 
proteoliposomes.  
 
Partitioning of substrates in to the lipid layer (egg PC vesicles) has been demonstrated 
to be dependent on cholesterol concentration (Eckford and Sharom 2008). Distribution 
of vinblastine between membrane and water (the membrane-water distribution 
coefficient, Klip) was highest without cholesterol and decreased about 6-fold when 
cholesterol concentration increased to 20 % (w/w). Also the Klip of verapamil, 
daunorubicin, Hoechst 33342 and rhodamine 123 decreased with increasing cholesterol 
concentration. In addition the affinity of the substrate to P-gp was decreased with 
increasing cholesterol concentration. This could explain why the Km- value of aliskiren 
was not managed to obtain in this thesis although Koskenkorva (2012) determined Km 
value of 5.05 µM for aliskiren with Sf9 vesicles without added cholesterol. Aliskiren 
showed very low permeability (0.056 x10-6 cm/s) in the MDCKII-MDR1 cells and the 
increased rigidity of the lipid layer could interfere with the distribution of aliskiren to 
the membrane and access inside the vesicles. As presented in the literature review the 
substrate binding happens in the lipid bilayer or from the cytosol. The fact that aliskiren 
transport is affected by cholesterol could mean that binding of aliskiren occurs in the 
lipid bilayer. 
 
As can be seen from Table 9 and Table 10 the detected concentrations inside the 
vesicles were low (magnitude of nM) even though powerful detection technique was 
used. This is one of the reasons why results obtained from vesicle assay are variable. In 
this work the ratio between passive and active transport was only 1.6‒2.6 which is why 
it is difficult to separate ATP-dependent and passive transport and see the effect of an 
inhibitor. Therefore according to the current study using vesicle assay for P-gp 
interaction studies is not possible because detecting small effect of inhibitor to substrate 
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transport rate would be very challenging. Vesicle assay could be used to recognize P-gp 
substrates. However the deviations of the vesicle assay results are great thus it cannot be 
said certainly which compounds are P-gp substrates. 
 
10.2 Quality tests for permeability assays 
 
In the current study the fluctuation of Lucifer yellow permeability values was great. 
Upper limit for Lucifer yellow Papp employed in this thesis was 1.0 x10
-6
 cm/s. The 
passages 13, 14, 16 and 17 used in the experiments Papp values varied from 0.047
 
to 1.0 
x10
-6
 cm/s. In one previous study with MDCKII-MDR1 cells of Lucifer yellow 
permeability limit values were 0.1 to 0.7 x10
-6
 cm/s (Zhang et al. 2006). The fluctuation 
in the current study was much greater and the maximum value higher than in the study 
of Zhang et al. The difference between the lowest and highest Lucifer yellow Papp value 
was approximately 20-fold which could have affected the quality of the results. 
Probably the variation of cell monolayer permeability has the most considerable effect 
on celiprolol permeability because it is the most hydrophilic test drug. The formation of 
the MDCKII-MDR1 cell monolayer has been suggested to have failed if Lucifer yellow 
permeability is over 0.5 x10
-6
 cm/s (Cyprotex 2013). This limit was exceeded in 
celiprolol and aliskiren experiments. In theory it is therefore possible that permeability 
of the two molecules is higher because of the leakier cell layer. All in all Lucifer yellow 
Papp varied from 0.047
 
to 1.2 x10
-6
 cm/s with passages 12-18. Experiment results where 
Lucifer yellow Papp was over 1x10
-6
 cm/s were discarded. The rapid increase in Lucifer 
yellow Papp values could be result from mycoplasma contamination which is difficult to 
observe visually. Mycoplasma bacteria contamination can affect the cell growth and 
therefore affect forming of the uniform cell monolayer (Ryan 1994).  
 
Concentration of DMSO seemed to have a moderate effect on permeability of Lucifer 
yellow. DMSO is a polar organic solvent which can penetrate biological membranes 
and therefore can increase the permeability of the cell monolayer. As expected the 
highest permeability resulted from DMSO concentration of 5 % and gave about 3-fold 
increase compared to 0 % DMSO. The maximal concentration used in the experiment 
was 0.6 %. The permeability difference was 2.3-fold between 0 % and 0.2 % which was 
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the DMSO concentration in most of the experiment. Maximal DMSO concentration 0.6 
% was used in aliskiren Km experiment. Furthermore the difference in Lucifer yellow 
controls between experiments was even 20-fold which implicates that effect of DMSO 
is minor compared to the effect of increasing passage number. According to Absorption 
Systems the test solution DMSO concentration should not exceed 0.8 % (Absorption 
systems 2013). This is in agreement with the current study. 
 
TEER values were rather low during the experiments. The average TEER value in the 
buffer before, and after the experiment was 62 ± 12 Ωcm2 and 61 ± 8 Ωcm2, 
respectively.  In one previous study the average TEER value of the MDCK-MDR1 cell 
monolayer cultured on polycarbonate  was 126 Ωcm2 (Williams et al. 2003). The values 
in the current study were lower which could indicate that there have been some 
problems with cell growth. Zhang et al. (2006) measured TEER values of 120-160 
Ωcm2 for MDCKII-MDR1-cells that had been grown on polycarbonate membrane. The 
origin of the cells in the experiment of Zhang et al. and current study was the same 
(Netherlands Cancer Institute) but the passage was higher in the current study (12-19 
compared to 5-9) which could explain the difference. No significant increase was 
detected between the values measured one day before (4
th
 day after the seeding) the 
experiment compared to the values measured just before the experiment (5
th
) day after 
the seeding) which is why it was decided to perform tests on 5
th
 day after seeding the 
cells on membranes. TEER did not show clear downward trend with increasing passage 
number although Lucifer yellow shower clear difference. From this can be concluded 
that Lucifer yellow is more reliable indicator of cell integrity but TEER value 
measurement is an easy method for identifying broken cell layers during experiments. 
 
Papp of paracetamol determined in this study is in agreement with previous studies. 
Permeability coefficient determined for paracetamol was 17.9 x10
-6
 which is very close 
to a previous determined value 17.4 x10
-6
 cm/s (A-B) (Cyprotex 2013). According to 
the BCS classification a drug is classified as a low permeable drug according its 
permeability and bioavailability (WHO 2005, FDA 2009). High permeable drug should 
have 90 % absorption from the intestine. According to previous studies the 
bioavailability of studied P-gp substrates is very low (Table 5). Reference drug 
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paracetamol is on the edge of high and low permeable drug and it has been classified as 
BCS I or III drug (WHO 2005, FDA 2009). The Papp values (A-B) of all the test drugs 
were all below the Papp of paracetamol thus based on these in vitro tests aliskiren, 
talinolol, celiprolol and fexofenadine can be classified as low permeability drugs.   
 
The variation between parallel samples was great in part of the experiments which 
needs to be considered in discussion. In addition number of parallel samples was very 
low (1-3) which is why calculating average and standard deviation does not necessarily 
show actual deviation. Part of the samples were diluted for the analysis which causes 
some inaccuracy for the analysis results which could be one of the reasons why 
recovery of compounds after cell experiment was low or in some cases irrationally high. 
The analysis method for P-gp substrates was not validated (accuracy and repeatability 
were not tested) because of the lack of resources thus it is not possible to evaluate 
reliability of analysis results. Also one problem was that samples were analyzed after 
variable time and compound could have decomposed during the storage.  
 
 
10.3 In vitro P-gp mediated efflux of test drugs 
 
The results from this thesis suggest that all the test drugs are transported with active 
mechanism. Fexofenadine, talinolol and celiprolol showed efflux ratio over 1 in 
MDCKII-MDR1 cells. According to FDA (2012) a drug is probably a P-gp substrate if 
its net efflux ratio is equal to 2 or higher. In this thesis talinolol and fexofenadine had an 
efflux ratio higher than 2 thus they fulfilled the FDA criteria. The efflux ratio of 
celiprolol was only 1.7 while no efflux ratio was managed to determine for aliskiren. On 
the other hand all the test drugs showed at least weak ATP dependent transport in the 
membrane vesicles. The amount of other transporter proteins beside P-gp in the used 
vesicles is low thus the active transport is probably mediated by P-gp (Sarkadi et al. 
1992). 
 
Further if also the efflux ratio of the test drug is decreased to half or to unity in the 
presence of known P-gp inhibitor, it is proven to be P-gp substrate (FDA 2012). In this 
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thesis the efflux ratio of celiprolol and fexofenadine was determined with P-gp inhibitor 
itraconazole. According to the result neither of the drugs seemed to be P-gp substrates 
because their efflux ratios were unaltered. Only fexofenadine permeability to the 
absorptive direction was very slightly increased (Error! Reference source not found.) 
hich resulted to 0.1 unit decrease in efflux ratio. However it is surprising that transport 
to the secretive direction is increased with both celiprolol and fexofenadine in the 
presence of itraconazole. More repetitions are needed to see if this is an analysis error or 
caused by inhibition of active transport. 
 
Saturation of the transport could explain the lack of inhibitor effect on permeability of 
celiprolol and fexofenadine. However used test concentrations (10 µ) were well below 
the Km-values of fexofenadine (150 µM) and celiprolol (1 mM) thus saturation of 
transport of these two drugs can be excluded (Karlsson et al. 1993, Petri et al. 2004). 
Another possible explanation for the absence of inhibitory effect is that the inhibitor is 
not present at concentration high enough to inhibit the binding of substrate to P-gp. 
Itraconazole concentration of 10 µM was used in all the experiments. In one previous 
work itraconazole concentration of 2.8 µM inhibited transport of cimetidine in 
MDCKII-MDR1 cells (Karyekar et al. 2003). Itraconazole inhibited also transport of 
digoxin with IC50 value of 1.3 µM in MDCKII-MDR1 cells (Keogh and Kunta 2006). 
On these grounds can be assumed that the concentration of 10 µM is sufficient. 
Itraconazole is metabolized by liver enzymes thus it is possible that in vivo inhibition is 
mediated by its metabolites (drugs@FDA). The metabolism is probably not occurring in 
MDCKII-MDR1 cells because there are very few metabolizing enzymes expressed in 
MDCKII-MDR1 cells (Quan et al. 2012). However since itraconazole has been shown 
to inhibit P-gp in MDCKII-MDR1 cell previously this explanation is not likely. 
 
In one previous study (Karyekar 2003) the cells were pre-incubated for 30 min with 
inhibitor while in this study the inhibitor and substrate were added at the same time. By 
pre-incubation with inhibitor can be ensured that inhibitor is present at P-gp binding 
places. It is possible that diffusion of the larger inhibitor (itraconazole molecular mass 
705.6 g/mol) can be slower in the cell membrane and therefore requires more time to 
get to the binding place. Itraconazole has also high lipophilicity (predicted logD7.4 4.29) 
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and it is insoluble in the water (Micromedex 2.0, ACD labs 8.08). Itraconazole stock 
concentration was prepared in DMSO without any problems and further diluted to 
aqueous transport buffer. However, the solubility was not controlled instrumentally thus 
it is possible that itraconazole was not soluble in test solution which would have 
prevented inhibitory the function.  
 
10.3.1 Transport of fexofenadine 
 
Fexofenadine (10 µM) Papp value 0.19 x 10
-6 
cm/s in the absorptive direction (A-B) was 
close to a fexofenadine (50 µM) Papp value of 0.17 x 10
-6
 cm/s determined earlier in 
Caco-2 cells (Petri et al 2004). On the other hand, the value for secretive direction (B-
A), 0.57 x 10
-6 
cm/s, differed greatly from the value of 14.22 x 10
-6
 cm/s Petri and 
coworkers determined. Therefore also efflux ratio determined in this work was also 
significantly lower (3.0 compared to 85). In Caco-2 cells, which Petri et al. used in their 
experiments, also other transporters are expressed in addition to P-gp. Fexofenadine has 
been suggested to be transported also by MPR2 and OATP transporters (Sasaki et al. 
2004, Sakugava et al. 2009, Akamine et al. 2012). The cellular uptake of fexofenadine 
was mediated by human OATP (Km 6.4 µM), rat Oatp1 (32 µM) and Oatp2 (6 µM) 
transporters in HeLa cells (Cvetkovic et al. 1999). The MPR mediated efflux along with 
P-gp mediated efflux in the caco-2 cells could explain the high transport rate to B-A 
direction. In addition OATP-mediated influx would explain why A-B transport is equal 
in current study and study of Petri et al. (2004) (despite the higher efflux caused by two 
efflux proteins). 
 
10.3.2 Transport of celiprolol  
 
In the study of  Karlsson et al. (1993) transport of celiprolol (50 µM) in the secretive 
direction was 5 times higher than transport in the absorptive direction in Caco-2 cells. 
Efflux ratio of celiprolol in this work was only 1.7 which indicates low P-gp mediated 
transport. However there was great variation in permeability values of celiprolol when 
studied alone and with cyclosporine and recovery in those experiments was low which 
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causes uncertainty in the results. When celiprolol was studied with cyclosporine the 
efflux ratio determined here decreased under unity (to 0.3 from 1.7) (Table 14) which 
could be result from an active uptake. Several studies suggest that celiprolol is OATP 
substrate Lilja et al. 2003, Lilja et al. 2004a, Lilja et al. 2004b, Uesawa and Mohri 2008, 
Kato et al. 2009. Significantly lower Km value was determined for celiprolol OATP-A 
mediated uptake in Xenopus Laevis oocyte than Km value for celiprolol secretion 
determined in caco-2 cells which refers to a greater affinity of celiprolol for the OATP 
than P-gp (Karlsson et al. 1993, Kato et al. 2009). However cyclosporine is also an 
inhibitor of OATPs, BCRP and MPR transporters thus it probably inhibited all these 
transporters (Agarwal et al. 2007, FDA 2012, Hillgren et al. 2013).   
 
10.3.3 Transport of talinolol 
 
Efflux ratio obtained from MDCKII-MDR1 cell experiment show here clearly that 
talinolol is a P-gp substrate. In this study the talinolol (10 µM) Papp (A-B) was 0.25 x10
-
6
 cm/s and Papp (B-A) 3.60 x10
-6
 cm/s.  Deferme et al. (2002) demonstrated Papp values 
of 1.08 x10
-6
 cm/s and 11.74 x10
-6
 cm/s for talinolol (100 µM) in Caco-2 cells for 
absorptive and secretive directions, respectively. The permeability coefficients of 
talinolol were clearly lower in this thesis but the efflux ratio was of the same magnitude 
(14 compared to 11). Also the Papp (B-A) increased about 3-fold by addition of P-gp 
inhibitor as in the study of Deferme et al. Lower expression of P-gp could be the reason 
why Papp values in this study are lower than in the study of Deferme’s group. Also lower 
test concentration explains the difference and it also seems that talinolol could have 
higher Km than 100 µM because efflux ratio is the same as with concentration 10 µM 
implicating that transport has not saturated. 
 
10.3.4 Transport of aliskiren 
 
Aliskiren concentration (2 µM) used in the cell experiment was too low thus transported 
amounts were undetectable. Papp value (A-B) was managed to determine with 
concentration 30 µM. Km value determined in membrane vesicles extracted from P-gp 
56 
 
expressing Sf9 cells was 5.05 µM (Koskenkorva 2012). Therefore it is possible that P-
gp mediated transport is saturated and Papp is the passive permeation. The results show 
that aliskiren has very low absorption (0.056 x10
-6 
cm/s) which implicates that it is more 
sensitive for the effect of transporters because the transporter has time to remove the 
drug from the cell membrane before new drugs penetrates through (Giacomini et al. 
2010). This explains why in vivo effect of P-gp inhibitor on aliskiren pharmacokinetics 
is great. 
 
10.4 Correlation of in vivo effect with in vitro results 
 
Correlation between in vitro and in vivo effect of P-gp inhibition can not be calculated 
because test compounds were not tested with an inhibitor in the vesicle assay test, and 
in the cell experiments permeability of test compounds (celiprolol and fexofenadine) 
was not affected by itraconazole. However there is some correlation between efflux 
ratios of substrates alone determined in vitro and increase of AUC in vivo when 
magnitude of the effect is compared between different substrates. Also some 
compounds had more clear ATP-dependent transport than other. 
 
In the vesicle assay aliskiren showed the highest ATP dependent transport (14 
pmol/mg/min) compared to other test drugs which is in agreement with its in vivo 
pharmacokinetics. Aliskiren AUC increased 6-fold with itraconazole while AUC of 
celiprolol and fexofenadine increases only 2-fold (Table 4). From aliskiren cell 
experiment results any conclusions cannot be made because the efflux ratio was not 
successfully determined. It would be interesting to repeat aliskiren experiments with 
higher concentration (2 µM was not detectable) to see if efflux ratio is higher than with 
celiprolol and fexofenadine.  
 
Talinolol showed the highest ATP dependent transport with the vesicles (4.7 
pmol/mg/min) after aliskiren and clearly greater transport to the secretive direction 
(efflux ratio 14). Also in vesicles the difference between passive and ATP-dependent 
transport was clear. In vivo results suggest that P-gp inducers increase the P-gp 
mediated transport of talinolol (Table 4). The in vivo effect of inducer is however low 
57 
 
(AUC decreases less than 50 %) compared to what could be expected according to 
efflux ratio determined in the current study when compared to efflux ratios determined 
to other substrates. For instance fexofenadine AUC increases 2-3-fold in vivo while in 
the current study it has efflux ratio 3.  
 
When in vivo and in vitro cell experiment result of celiprolol and fexofenadine are 
examined it can be seen that they correlate with in vivo studies. According to cell 
experiments celiprolol (efflux ratio 1.8) absorption is less dependent on P-gp efflux than 
fexofenadine (efflux ratio 3). In vivo the effect of itraconazole is also minor to the AUC 
of celiprolol (AUC increases 1.8-fold). It must be noted however that drug recovery in 
celiprolol cell assay was low (B-A 70 % and A-B 79 %) which could have affected the 
results. Either way also in vesicle assay celiprolol showed lower ATP dependent 
transport rate compared to fexofenadine and talinolol, and low affinity to P-gp (Km 
higher than 100 µM). 
 
11 CONCLUSIONS 
 
P-glycoprotein is expressed in organs which participate on drug absorption, distribution 
and elimination and P-glycoprotein mediates clinically significant interactions in vivo. 
The object of this thesis was to understand P-gp mediated drug interactions. In the 
literature part structure, function, regulation and substrate selection of P-gp was 
reviewed in order to understand complexity of P-gp. The structure of P-gp is studied 
widely and recent crystallization of mouse P-gp is big step towards knowing the 
structure of human P-gp. With the help of protein crystal structure P-gp interacting 
molecules can be screened computationally. Screening P-gp substrates and inhibitors is 
challenging because P-gp has several binding sites. When studied P-gp interactions with 
the help of computational methods the interactions should be screened by fitting each 
molecule combinations to the binding cavity. 
 
In the experimental work P-gp mediated interactions of four P-gp substrates were 
studied with two in vitro methods and results were compared to in vivo interactions. 
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Vesicle assay method was able to show ATP dependent transport for all studied P-gp 
substrates in P-gp expressing vesicles. In addition in MDCKII-MDRII cells celiprolol, 
talinolol and fexofenadine showed an efflux ratio higher than 1 in which means that 
they have active transport. However there was no interaction detected between P-gp 
inhibitor itraconazole and P-gp substrates fexofenadine and celiprolol thus they do not 
meet the criteria of FDA for P-gp substrates. The reason for lack of interaction could be 
unsuccessful performance of the experiments (such as lack of pre-incubation with 
inhibitor) and not the lack of P-gp efflux.  
 
According to results obtained here in vivo significance of drug interaction cannot be 
predicted. However some results obtained with in vitro vesicle assay, cell assay and in 
vivo studies are in line with each. Both vesicle assay and in vivo studies suggest that 
aliskiren is a good P-gp substrate while all the methods suggest that celiprolol is a poor 
substrate. In vitro cell assay showed that talinolol was a good substrate for P-gp 
although in vivo results with inhibitors are not available. Fexofenadine seemed to be P-
gp substrate in both in vitro assays in accordance with in vivo studies. According to this 
thesis vesicle assay and cell assay can be used to recognize P-gp substrates. However 
significance of P-gp mediated interactions is difficult to predict because of high variable 
results of both assays.  
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APPENDIX 1   
 
PERMEABILITY OF P-GLYCOPROTEIN SUBSTRATES IN MDCKII-MDR1 
CELLS  
 
Figure 1. Transport of fexofenadine 10 µM through MDCKII-MDR1 cell monolayer 
from the apical to the basolateral side (A-B) and from the basolateral to the apical side 
(B-A) 
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Figure 2. Transport of talinolol 10 µM through MDCKII-MDR1 cell monolayer from 
the apical to the basolateral side (A-B) and from the basolateral to the apical side (B-A)  
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Figure 3. Transport of celiprolol 10 µM through MDCKII-MDR1 cell monolayer from 
the apical to the basolateral side (A-B) and from the basolateral to the apical side (B-A)  
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Figure 4. Transport of aliskiren 30 µM through MDCKII-MDR1 cell monolayer from 
the apical to the basolateral side (A-B)  
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PERMEABILITY OF P-GLYCOPROTEIN SUBSTRATES WITH INHIBITORS IN 
MDCKII-MDR1 CELLS 
 
Figure 1. Transport of fexofenadine 10 µM with itraconazole 10 µM through MDCKII-
MDR1 cell monolayer from the apical to the basolateral side (A-B) and from the 
basolateral to the apical side (B-A). 
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Figure 2. Transport of celiprolol 10 µM with itraconazole 10 µM through MDCKII-
MDR1 cell monolayer from the apical to the basolateral side (A-B) and from the 
basolateral to the apical side (B-A)    
y = 3E-06x + 0,0078 
R² = 0,9634 
0,000
0,005
0,010
0,015
0,020
0,025
0,030
0,035
0 5000 10000
C
u
m
u
la
ti
v
a
 a
m
o
u
n
t 
(n
m
o
l)
 
Time (s) 
Celiprolol 10 µM + 
itraconazole 10 µM, A-B 
well 1 
y = 3E-06x + 0,0082 
R² = 0,9092 
0,000
0,005
0,010
0,015
0,020
0,025
0,030
0 5000 10000C
u
m
u
la
ti
v
e 
a
m
o
u
n
t 
(n
m
o
l)
 
Time (s) 
Celiprolol 10 µM + 
itraconazole 10 µM, A-B 
well 2 
y = 2E-06x + 0,0045 
R² = 0,9927 
0,000
0,005
0,010
0,015
0,020
0 5000 10000
C
u
m
u
la
ti
v
e 
a
m
o
u
n
t 
(n
m
o
l)
 
Time (s) 
Celiprolol 10 µM + 
itraconazole 10 µM, A-B 
well 3 
y = 1E-05x - 0,0062 
R² = 0,9806 
0,000
0,020
0,040
0,060
0,080
0,100
0 5000 10000
C
u
m
u
la
ti
v
e 
a
m
o
u
n
t 
(n
m
o
l)
 
Time (s) 
Celiprolol 10 µM + 
itraconazole 10 µM, B-A 
well 1 
y = 2E-05x - 0,0189 
R² = 0,9822 
0,000
0,020
0,040
0,060
0,080
0,100
0,120
0 5000 10000
C
u
m
u
la
ti
v
e 
a
m
o
u
n
t 
(n
m
o
l)
 
Time (s) 
Celiprolol 10 µM + 
itraconazole 10 µM, B-A 
well 2 
y = 9E-06x + 0,0103 
R² = 0,9924 
0,000
0,020
0,040
0,060
0,080
0,100
0 5000 10000
C
u
m
u
la
ti
v
e 
a
m
o
u
n
t 
(n
m
o
l)
 
Time (s) 
Celiprolol 10 µM + 
itraconazole 10 µM, B-A 
well 3 
  
APPENDIX 2 
 
Figure 3. Transport of celiprolol 10 µM with cyclosporine 10 µM through MDCKII-
MDR1 cell monolayer from the apical to the basolateral side (A-B) and from the 
basolateral to the apical side (B-A).  
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Figure 4. Transport of talinolol 10 µM with cyclosporine 10 µM through MDCKII-
MDR1 cell monolayer from the apical to the basolateral side (A-B). 
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PERMEABILITY OF PARACETAMOL IN MDCKII-MDR1 CELLS  
 
Figure 1. Transport of paracetamol 50 µM from the apical to the basolateral side (A-B) 
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LUCIFER YELLOW STANDARD CURVE 
 
Figure1. Standard curve of Lucifer Yellow 
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PERMEABILITY OF LUCIFER YELLOW IN MDCKII-MDR1 CELLS 
 
Figure 1. Permeability of Lucifer yellow 250 µM from the apical to the basolateral side 
(A-B) during talinolol permeability determination.  
 
 
 
Figure 2. Permeability of Lucifer yellow 250 µM from the apical to the basolateral side 
(A-B) during fexofenadine and paracetamol permeability determination.  
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Figure 3. Permeability of Lucifer yellow 250 µM from the apical to the basolateral side 
(A-B) during celiprolol permeability determination.  
 
 
Figure 4. Permeability of Lucifer yellow 250 µM from the apical to the basolateral side 
(A-B) during aliskiren permeability determination  
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Figure 5. Permeability of Lucifer yellow 250 µM from the apical to the basolateral side 
(A-B) with DMSO concentrations (v/v) of 0%, 0.1%, 0.2% and 5%. (Upper row 
passage 13, lower rows passage 16)  
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AVERAGE TEER VALUES DURING CELL EXPERIMENTS 
 
Figure 1. Average (±SD) TEER (trans-epithelial electrical resistance) values before cell 
experiments in cell culture media and transport buffer, and after experiments in transport buffer 
Experiment 
Before experiments 
TEER (Ωcm2) (average ± SD) 
TEER after experiment 
TEER (Ωcm2) (average ± SD) 
Culture media Transport buffer Transport buffer 
Talinolol 73 ± 16 - 75 ± 14 
Celiprolol 87 ± 6 58 ± 7 71 ± 7 
Aliskiren 53 ± 9 70 ± 6 59 ± 9 
Fexofenadine 
and paracetamol 
69 ± 6 68 ± 7 65 ± 8 
 
